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Abstract
Metal ions are ubiquitously found in all living systems and play vital roles in supporting life
forms by performing an array of biological activities. Such biological activities include binding
and transforming organic molecules, and also acting as active centers and cofactors for catalysis
of various acid-base and redox reactions in biological system. The main focus in bioinorganic
chemistry is to elucidate the structural and functional roles of metals in biological systems.
Among all transition metal ions, Cu2+ and Fe3+ are especially versatile and important due to their
abilities to go through redox efficiently.
This dissertation can be divided into four main chapters. The bioinorganic chemistry of Cu- and
Fe-containing proteins were briefly discussed in Chapter one. The next chapter focuses on
bacitracin, a cyclic peptide-based antibiotic produced by soil bacteria Bacillus subtilis. Bacitracin
is a metalloantibiotics that can coordinate with many transition metal ions and exhibit different
biological activities. In the first part of Chapter two, the aim is to explore the chemicals
interactions in soil micro-ecology by investigating the interactions of different flavonoids and
Cu(II)-bacitracin complex. The second part of chapter two demonstrated the binding and
oxidation activity of iron(III)-bacitracin. Metal-mediated oxidative stress plays a crucial role in
the development of different neurodegenerative diseases. In chapter 3, various synthetic and
natural compounds were used to inhibit the oxidation chemistry mediated by Cu(II)-betaamyloid complex associated with Alzheimer’s disease. Many proteins incorporate copper ions at
xiii

their active sites for different functions, and among all of the chemistry copper-containingproteins can perform, one of the most interesting aspect is the ability to bind and activate O2.
Therefore, the biomimetic of two different Cu(II) complexes were investigated. In all studies, a
combination of kinetic and different spectroscopic methods (UV-vis, NMR and resonance
Raman spectroscopy) were used to study their metal binding and activity.
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Chapter 1 Peptides and Metals: A Brief Overview
Introduction to Metallopeptides
Bioinorganic chemistry focuses on elucidating the structural and functional role of metals
in various biological systems. Many metal ions play crucial roles in supporting life forms by
being responsible of binding and transforming organic molecules while also acting as active
centers and cofactors for catalysis of extensive acid-base and redox reactions in biological
systems.1 Chemists have been building model systems that are associated with metal ions and
related ligands, among which the study of interactions of amino acids and peptides with metal
ions attracts the most attention.2 Amino acids bind with each other through linking by peptide
bonds, forming various sequences of peptides and proteins which could potentially interact with
the transition metal ions.1 There are several ways for peptides to interact with metals their through
the peptide backbone or functional side chains. For example, in Figure 1.1.a, metal ion
coordinates through the α-amino and carboxylate moiety to form a five-membered chelate ring. In
the dipeptide situation shown in Figure 1.1.a, metal ion can coordinate with the terminal
carboxylate moiety and terminal amino moiety. Another way amino acids interact with metal ions
is through their side chains. Transition metals are Lewis acids, which accept electrons into their
empty valence orbitals. Under deprotonation condition, some amino acids can serve as good
Lewis bases coordinating with metal ions and influencing the oligopeptide coordination
environments. Many amino acid side chains contain ideal metal binding sites, such as the
imidazole moiety on histidine, thiol moiety on cysteine, carboxylate moiety on aspartic acid and
glutamic acid respectively, phenol moiety on tyrosine, and thioether moiety on methionine
1

(Figure 1.2).1, 3 Transition metals play crucial roles in many biological systems by performing
electron transfers, signaling, DNA transcription, various storage and catalytic activities.4 For
example, Zn finger is a small protein structural motif that interacts with DNA for gene
regulations. Its metal-binding active site contains two histidines and two cysteine residues that
coordinate to the Zn(II) center, stabilizing the folded structure (Figure 1.3).5 In the field of
peptidomimetics, researchers have focused on preparing, investigating and characterizing the
structural and catalytic activity of peptide-based transition metal complexes for better
understanding of the role of metals in proteins.6

Figure 1.1: Metal binding to amino acid
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Figure 1.2: Amino acids that can potentially interact with metal ions.

Figure 1.3: X-ray crystallography structure 2-His (displayed in blue rings) and 2-Cys (displayed
in yellow) active site of zinc finger(PDB ID: 1A1L).5

3

Metalloantibiotics

Antibiotics interact with various biomolecules through several different modes of physical
and chemical interactions leading to inhibition of those biomolecules including DNA,7 proteins,8
nucleic acids,9 or biomolecules. For example, the antibiotic anthracycline is used in anticancer
therapy often since it inhibits the gene replication by intercalating into DNA base pairs. 10
Although many antibiotics do not require metal ions to perform their biological functions, there is
a group of natural and synthetic antibiotics that required metals to be bioactive and hence termed
“metalloantibiotics.”11 Activities of these metalloantibiotics are strongly related to the metal ions.
Usually upon metal binding, there are various degrees of structural conformation changes which
can affect their function; modification at metal binding site or removal of the metal ion will affect
overall structural integrity and lead to decrease or complete loss of activity. 11 The use of
antibiotics started in early 1940s, and over time, bacteria have developed various resistances
toward the antibiotics, leading to serious medical consequences. One way Center of Disease
Control and Prevention (CDC) has proposed to halt bacteria resistance is to develop new drugs
based upon the chemical characterization of bio-active lead compounds and their analogues.12 To
do so, it is important to understand the structure and activities of a bio-active lead compounds in
order to design more efficient drugs.
Bleomycin (BLM) (Figure 1.4)—also known as blenoxane—was first isolated from a
culture medium of the soil bacteria strptomyces verticullus as a copper(II)-containing
glycololigopeptides antibiotic.13 Copper(II)-containing bleomycin showed antiviral activity.14
BLM was later shown that upon chelation of iron(II), it can be used toward anticancer treatments,
especially targeting testis cancer, and head and neck cancer, and lymphomas.15 With the
combination of cisplatin, adriamycin and vincristine and metallo-bleomycin, can treat Kaposi’s
4

sarcoma, which is associated with ADIS.11,

16

The structure of bleomycin includes two sugar

moieties, some uncommon amino acid like β-aminoalaine, β-hydroxylhistidine, methyl valerate,
and several potential metal binding sites; the two thiazole moieties in the end are considered to be
the recognition site for DNA and RNA.11 Besides Cu2+ 17 and Fe2+/3+,18 bleomycin coordinates
with many other metal ions including Co3+/2+,19 Mn2+,20 Ni2+/3+,21 Zn2+,22 Cd2+,23 Ga3+
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and

Ru2+.25

Figure 1.4: Structure of bleomycin (The bold-N are considered as the metal binding sites based
on spectroscopic methods).

Cu Chemistry
Copper is one of the most biologically important metal ions and usually exists in three
oxidation states: Cu1+ and Cu2+ are the most common, while Cu3+ is less common. Cu(I) is
diamagnetic and has an electron configuration of d10, in which the d orbital is completely filled
5

and is less sensitive to coordination topology.4 Cu(I) tends to form stable three- and fourcoordinated complexes, rarely forming five-coordinated complexes. The geometry of Cu(I)
complexes is controlled mostly by steric hindrances and structural constraints, and can form
various geometries depending on the ligands and environments—although, octahedral, trigonal,
tetrahedral and trigonal pyramidal are the most commonly observed geometries.26 The electron
configuration of Cu(II) is d9, thus having one unpaired electron which makes Cu(II)
paramagnetic. Cu(II) is a strong Lewis acid compared to Cu(I) and can adopt different geometries
based on various chemical foundations, including ligand field theory. Commonly seen geometries
of Cu(II) complexes are square planar, square pyramidal, trigonal bipyrimidal and octahedral.13a
Due to the unpaired electron in degenerate orbitals in Cu(II), significant Jahn-Teller effect occurs
that further distort the geometry in order to gain stabilization. For example, when Cu(II) forms
complex in an octahedral geometry, significant Jahn-Teller effect is observed, and this is due to
the uneven electrons distributions in the doubly-degenerated eg orbitals of Cu(II), which also
leads to Cu(II)-complex distortion either by elongation along dz2 or contraction.1, 4, 26
The Role of Copper in Bioinorganic Chemistry

Copper is ubiquitously in biological systems including plants, mammals, bacteria and
fungi. Copper ions are usually incorporated into proteins, acting as a cofactor for performing
various biological activities.4 What makes copper so versatile is its ability to bind and/or activate
O2, and its participation in cellular pathways. Nature has developed many copper containing
enzymes for activation of dioxygen functions including monooxygenases, dioxygenases and
oxidases.26
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Copper participates in various biochemical processes that support life, and the copper
concentration in our body is strictly regulated. Copper can be found extensively in almost every
body tissues, and are mostly stored in muscles, brain, liver, kidney and heart.4 Copper is absorbed
through the stomach and small intestine, where the typical copper absorption is around 40-60% in
humans.27 High concentrations of free metal ions such as Cu(II) can generate significant amounts
of reactive oxygen species, leading to serious cytotoxicity. Metal concentrations in the biological
system are strictly regulated due to their potential threat. For the case of copper overload, which
causes Wilson’s disease, it is a genetic disease where copper in excess amount accumulates in
liver, brain, kidney, cornea and other tissues, causing local damage to the areas, and treatment for
it includes strict diets and administration of a metal chelator.28 Severe forms of Wilson’s disease
could lead to liver and kidney failure. In the case of copper deficiency, Menkes disease is a
recessive gene disorder; the patients often have sparse and brittle hair, low muscle tone
(hypotonia), seizures and uncontrollable muscle movements, slow intellectual development, and
deterioration of the neuron-system.27, 29
There have been extensive studies focusing on the involvement of metal ions in
neurodegenerative diseases.30 When there is a disruption in the regulation of metal concentration,
significant oxidative stress is generated from excess metal ions, especially in the case of Cu(II)
due to their high redox potential. Oxidative stress is considered to be one of the culprits of many
neurodegenerative diseases.30c Redox metals such as Cu(II), Fe(III) and Zn(II) have been
observed in the cerebral cortex, where beta-amyloid deposits—commonly associated with
Alzheimer’s disease—were found with concentrations up to 0.4 mM for Cu(II) and around 1 mM
for both Fe(III) and Zn(II).31 The presence of these metal ions induces the aggregation of amyloid
plaques, further leading to neuron-death.31a, 32 Copper also plays a role in Parkinson disease, as
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studies have shown that α-synuclein tends to aggregate in the similar fashion as β-amyloid,
especially in the presence of Cu(II), Al(II), Fe(III) and Mn(II).33
Mononuclear and Dinuclear Copper Proteins

It is important to understand the coordination environment of copper, in enzymes and
proteins

since

they

can

provide

useful

information

about

their

structure

activity

relationships.Copper ions in enzymes usually act as the active center. Copper-containing proteins
can be classified into three types: type-1, type -2 and type-3.
Type 1 proteins are a group of small mononuclear proteins with a single copper ion at
their active sites, and are efficient in performing electron transfers. They are also known as “blue
copper proteins” due to the intense blue color they exhibit.34 The intense blue color is attributed to
the ligand-to-metal charge transfer from the sulfur atom on cysteine to Cu(II). The electronic
spectrum of a classical type 1 copper protein shows intense absorption band around 600 nm in
UV.4 Type 1 copper proteins usually adopt a distorted tetrahedral geometry and the active site
coordination environment usually consists one cysteine, two histidine and an axial methionine.35
An example of a type 1 copper blue protein is plastocyanin which was the first blue copper
protein whose structure was characterized by X-ray crystallography.36
Type 2 copper proteins usually have a Cu(II) ion center coordinating to various amino
acids, forming different geometry where most of the time the structure is a tetragonal-distorted
geometry.37 Examples of type 2 copper proteins are dopamine monoxidase and Cu,Zn-superoxide
dismutase. For type 3 proteins, are typically consist of two copper(II) ions bridged by a water
molecule or a hydroxyl group in the active site. Both type 2 and type 3 copper proteins are
involved in oxidation and oxygenation activities. In the case of ascorbate oxidase, the enzyme has
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four copper ions incorporated into the structure; it contains all three types of copper sites (Figure:
1.5).1,

4, 26, 38

Among all copper-containing proteins that can perform Cu-O2 chemistry, in the

following sections selected dinuclear and mononuclear copper proteins will be briefly discuss.

Figure 1.5: Different types of copper containing proteins and their coordination environments.
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Mononuclear copper proteins have one copper center in their active site. A seemly simple,
yet complex reaction of O2 coordinating to a Cu(I) site, produces a Cu-O2 species that can activate
O-O bond cleavage or act as an electrophile toward organic substrates.39 There have been many
attempts to trap the intermediate and with low-temperature stopped-flow kinetic studies of Cu(I)
complex oxygenation, and some 1:1 adducts were isolated and characterized by means of various
spectroscopic methods. From which, possible arrangements of intermediates and some key bond
distances were obtained as shown in Figure 1.6.26, 39-40

Figure 1.6: Possible binding modes and distances of Cu/O2 center.
Cu,Zn-Superoxide dismutase (SOD) is a mononuclear copper protein that contains one
zinc and one copper ion at its active site.37, 41 Cu, Zn-SOD is categorized as a type 2 copper
protein and is responsible for the disporportionation of highly reactive superoxide (

) to yield

oxygen (O2) and hydrogen peroxide (H2O2).37 It is a very essential enzyme which controls the
generation of free radicals in biological system whereas other reactive oxygen species such as
hydrogen peroxide can be broken down by enzymes like catalases.1 Cu, Zn-SOD is found in all
10

living organisms with the exception of some oxygen sensitive organisms, like obligate anaerobes.
Cu, Zn-SOD is present in both bacteria and eukaryotes; for bacteria Cu-Zn-SOD is found in the
periplasmic space, existing mostly in the nuclei, peroxisomes lysosomes, cytosol and transmembrane space of mitochondria.42 The first x-ray crystallography structure of Cu-Zn-superoxide
dismutase was reported in 1979 by Richardson and his group (Figure 1.7).43 From the x-ray
structure, Cu and Zn are 6 Å away and situated one side of the β barrel, bridged by a deprotonated
μ-histidine between them. The Cu center is coordinated to four histidine ligands with distorted
square planar geometry. Three histidines and one aspartate coordinated to Zn(II) in a distorted
tetrahedral geometry.43

Figure 1.7: X-ray crystallography structure of Cu, Zn dismutase (PDB ID: 2SOD).44
The reactions catalyzed by Cu, Zn-SOD can be described in Equation 1.1 and 1.2. The
first part involves reduction of Cu(II) to Cu(I) and oxidation of superoxide to oxygen, then the
second step involves the oxidation of Cu(I) back to Cu(II) and reduction of superoxide.4 Zn2+ does
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not directly participate in the redox cycle—instead, it maintains the overall structure of the
enzyme.4 Cu, Zn-SOD is usually present in dimer form in mitochondria, cytoplasm and
extracellular space in almost all eukaryotes. Formation of mutated dimer structures hinders its
activity.41b The neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), also
known as Lou Gehrig's disease, is linked to some mutations of Cu, Zn-SOD and impaired ability
to secrete copper ions, which are important for catalyzing the dismutation of superoxide.45 It is an
irreversible neurodegenerative disorder that is associated with mutations in the Cu, Zn-SOD gene,
sod1.46 The mechanism of Cu, Zn-superoxide dismutase is provided in Figure 1.8 that highlights
the importance of a distal Arg residue and the bridging His.

Equation 1.1

Equation 1.2
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Figure 1.8: Mechanism of Cu, Zn-SOD.
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Catechol oxidase is also known as o-diphenol oxidase and 1,2-benzenediol oxygen
oxidoreductase, and is responsible for catalyzing the oxidation of various o-diphenol related
compounds to their corresponding oxidized o-quinone products.47 The o-quinones usually
accumulates, cross-linked and aggregate, forming polyphenolic pigments with a brownish color,
such as melanin, which is the built up of polyphenolic pigments. Catechol oxidases are
ubiquitously found in plants, insects and crustaceans.48 Catechol oxidases can be divided into two
main groups based on their molecular mass due to C-terminus processing, where one group
ranges from 38 to 45 kDa and the other ranging from 55-60 kDa.49 Solomon and Krebs both
proposed a similar catalytic cycle mechanism for catechol oxidase activity (Figure 1.9).50 Krebs
reported that, from the x-ray crystal structure of catechol oxidase in its catalytic state, it can adopt
two states including the native met form and reduced de-oxy form.51 For the met state, both copper
centers are at 2+ oxidation states and have a distance of 2.9 Å between them according to
Extended X-Ray Fine Absorption Structure (EXFAS) results.50a, 51 For the deoxy state, both Cu(II)
are reduced to Cu(I), with the distance between the two metal centers increasing to 4.4Å. The
catalytic cycle of catechol oxidase starts with the met form allowing one catechol molecule to
bind and release the first o-quinone product, then reduced the two Cu(II) ions to deoxy form with
two Cu(I) centers allowing O2 to bind. There are also several different modes that catechol can
bind to the copper centers shown in Figure 1.10.52
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Figure 1.9: Catechol oxidase mechanism proposed by Krebs and Solomon.50e
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Figure 1.10: Possible binding modes of catechol to copper proteins.52

When dioxygen binds to the reduced Cu(I) centers, it immediately forms a highly active
peroxo-dicopper(II) intermediate.53 In summary, there are three possible structures of the dicopper
center with a bound dioxygen and the distances between atoms have been determined (Figure
1.11).26, 50c
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Figure 1.11: Possible modes of dioxygen binding to di-copper center and the distances between
atoms (distance unit is in Å).
Tyrosinase is a type 3 copper-containing enzyme that can bind and activate dioxygen,
producing variouso-diphenols (path A) and ortho-quinones (path A+B), with the ortho-quinones
further polymerizing, forming melanin.54,55 The active site contains two copper ions, each
coordinated to three histidines. The overall active site has a trigonal pyramidal geometry;
dioxygen coordinated to both metal centers with peroxy bridging, having a distance of 3.4
angstroms in distance between the two copper centers.4 Tyrosinase follows two kinds of oxidation
mechanisms: monooxygenase and oxidase activities (Figure 1.12). There are several characteristic
states during the catalytic cycles including oxy, deoxy, and met forms; the overall catalytic scheme
is provided in Figure 1.13.54
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Figure 1.12: The two modes of tyrosinase-catalyzed oxidation.

Figure 1.13: The cooperatively catalytic cycle of oxidation states of tyrosinase.56
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Fe Chemistry
Out of all of the transition metals, iron is one of the most extensively studied metals in the
living system. Due to its abundance and high redox potential, iron is found ambitiously in large
number of organisms in many biological systems. Beside oxygen, silicon and aluminum, iron is
the fourth richest element in the Earth’s crust, of which iron makes up 4.7% by weigh.4 Iron has
the ability to go through redox easily; the common forms of iron are the ferric (Fe3+) and ferrous
(Fe2+) states. Iron can also go to higher oxidation states such as Fe4+ and Fe5+ during high valence
intermediate steps. Ferric iron has high affinity toward hydroxyl moiety and tends to be insoluble
in aqueous environments, while ferrous iron has higher solubility and a high affinity toward O2
.For example, the redox potential of Fe(III) at neutral pH in aqueous system (
is –230 mV while under aerobic conditions with O2 being a strong oxidizer, the redox potential of
is +820 mV.4 Iron is a very versatile metal which adopts various
geometries, including six-coordinated octahedral, distorted five- or four-coordinated tetrahedral
geometry.4, 57 Iron has coordination numbers of 3, 4, 5 and 6 which can coordinate with various
ligands. A free ferric ion has an ionic radius of 67 pm and electron configuration of d5, it is
considered to be strong Lewis acid, which interacts with hard Lewis bases like the phenolate
moiety from tyrosine, and the carboxylate moiety from aspartic acid and glutamic acid. For a free
ferrous ion, its ionic radius is 83 pm and is between the borderline of a hard or soft acid, and
tends to interact with nitrogen containing ligands such as histidine, cysteine, and methionine side
chains.57 Another property of iron which makes is so unique is the relatively easy spin crossover
between high- and low-spin states. This ability to readily switch from different spin states allows
the molecule to be flexible enough to go through catalytic reactions involving redox reactions and
ligand exchanges without disturbing the overall structural integrity.1, 4
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All biological systems require iron to sustain life; however, at the same time iron can also
be very toxic and may lead to death if not regulated and/or treated.58 In an adult human body,
there are about 3 to 4 grams of iron; two-thirds of that is responsible for the composition of
hemoglobin in red blood cell and recycled iron generated through the red blood cell destruction,
while the remaining one-third is stored in the iron storage protein ferritin, while very minute
amounts of iron (1-2 mg) are absorbed through our intestinal tract.59 The concentration of iron is
strictly regulated, and misregulation of it will lead to serious life threatening issues. There are
several critical factors to consider when it comes to the misregualtion of iron concentration in
human body including erythroid mutation, dysfunctional iron transport and external exposure
factor such as excess blood transfusion.58b,

59-60

In the case of iron overload, also known as

haemochromatosis, a significant amount of reactive oxygen species are generated through
accumulation of iron, eventually leading to organ dysfunctions.61 There are two types of
haemochromatosis: primary—which is hereditary or genetically determined; and secondary,
which is obtained after birth.58b There are many studies which report the involvement of metal
ions in many neurodegenerative diseases. For example, there are high amounts of Cu2+, Fe3+ and
Zn2+ observed in the amyloid plaques of Alzheimer’s disease patients, and the presence of metal
increases the oxidative stress and aggregation of amyloid plaques.30c, 31a Iron deficiency is one of
the most common forms of malnutrition and untreated overtime can lead to anemia; it is described
as having insufficient erythrocytes or hemoglobin.62
All living organisms require iron to sustain life, and iron plays a crucial role in the early
development of life forms. About 4 billion years ago, CO2, N2 and H2O were the main
components of Earth’s primordial atmosphere, with trace amounts of CO, H2, CH4, O2, CH3SH
and H2S.4 During that time, iron existed mainly as the forms of pyrite iron(II)-persulfide, troilite
20

FeS, pyrrhotite Fe1-x and pentlandite (Fe,Ni)9S8.63 When FeS encounters CH3SH and CO2, it
produces water, FeS2 and the methyl ester of thioacetic acid, also known as the active acetic acid.
Thioacetic acid methyl ester is similar to acetyl-CoA, co-enzyme that transfers the acetyl moiety
to citric acid in the Krebs cycle to be oxidized for generation of energy. Furthermore, when
thioacetic acid methyl ester interacts with aniline, they form the anilide of acetic acid in which the
amide bond in it mimics the peptide bond linkage (Figure 1.14).4 Iron ions are Lewis acid
accepting electrons from various Lewis base ligands such as sulfur. Another example which
demonstrates the fundamental importance of iron is the self-assembling formation of cuboid ironsulfur clusters, which is the basic analogue of a group of Fe-S cluster proteins.8, 64
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Figure 1.14: FeS interaction with methanethiol, CO and CO2.4

The Role of Iron in Bioinorganic Chemistry

Due to the overwhelming amounts of hydroxyl moiety and strong binding affinity toward
the ferric center in aqueous systems, ligand competition toward the iron center is difficult due to
the low solubility of Fe(OH)3 at pH 7.63 Ferrous is soluble in aqueous systems at neutral pH and is
available for organisms to uptake, while some biological systems, such as some bacteria and
yeast, have designated uptake systems for transporting Fe(II).65 Iron is essential for life, and
different organisms have evolved and developed strong chelators to secrete iron into their
systems. In this section, the activity and structure of two classical iron-transfer proteins,
siderophore and transferrin, and one iron-storage protein ferritin from different biological systems
will be discussed.
In the natural environment, with the presence of oxygen and water molecules, ferric oxide
hydrate complexes are the predominant species for ferric complexes. The Ksp value of ferric
hydroxide is 10–39 mol4 L–4 and at pH 7, Fe3+ concentrations are in the range of 10–18 to 10–19 mol
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L–1, leaving very limited amounts of iron available.4 All organisms require iron to survive, and
they have developed high iron binding affinity compounds which act as iron chelators for iron
uptake. Siderophores are small molecules with high binding affinity toward iron produced by
bacteria, fungi and grasses due to low amounts of available soluble iron ferric. They are
synthesized through nonribosomal peptide synthetases. They can be categorized into three major
groups based on the different oxygen donors including catecholate and phenolate, hydroxamate or
(α-hydroxyl-)carboxylate containing moieties. A few representatives siderophores are provided in
Figure 1.15.65 Fe3+-siderophore complexes are usually globular and hydrophilic on the periphery
in order to increase their solubility in aqueous environments. Once Fe3+-siderophore complexes
encounter the cells, they are taken up by receptors on the cell walls to further transport it towards
the cytosol.65 Fe3+ can be released into the system by siderophore degradation or reduction of
ferric to ferrous center, which has very low affinity toward siderophore. Enterobactin is a
siderophore produced by Escherichia coli and is one of the strongest Fe3+ chelator with a
formation constant around 1050 M–1.66

Figure 1.15: Representations example of different types of siderophores.
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Transferrin is responsible of transport iron within the human body. The human apotransferrin (metal-free), hTfH2, is a glycoprotein with a molecular mass of 80 kDa (Figure 1.16).67
The active site coordination environment consists of ferric iron binding to two tyrosines through
the phenol moiety, one aspartic acid through the carboxylic moiety and one histidine binding
through NƐ on imidazole ring with an overall octahedral geometry.68 A carbonate ion is absolutely
essential for tight binding of Fe with the protein.The stability constant of Fe3+-transferrin complex
at physiological pH 7.4 is 1020 M–1.4 Once transferrin is complexed with saturated amounts of
iron, it transports the iron to various sites for further use such as delivering iron to a precursor of
the heme moiety in haemoglobin. The complex releases iron by going through reduction reaction
from ferric to ferrous, mediated by compounds like ascorbic acid.61

Figure 1.16: Crystal structure of human serum transferrin (Ferric center is displayed as the green
ball) (PDB ID: 1D3K).69
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Due to the potential to generate reactive oxygen species through various pathways,
including the Fenton reaction, unregulated iron poses serious cytotoxicity. Unused and excess
iron is stored in an iron storage protein known as ferritin.4 Ferritin is large, hollow sphere-like
protein arranged by arrays of self-assembling subunits comprised of α helices with nano-scale
cavities ranging from 5 to 8 nm. Ferritin can be found ubiquitously in plants, microorganisms and
animals. Up to 4500 iron atoms can be stored within the mineral inside the protein cage of ferritin,
with the involvement of oxygen by bridging oxo and hydroxo groups.60 The human apotransferrin is 450 kDa in molecular mass and consists of 24 subunits; the outer and inner
diameters of it are 130 and 75 Å (Figure 1.17). The inner layer of the protein and the surface of
cavities are rich in carboxylates containing amino acids, like glutamic acid and aspartic acid,
which coordinate with iron in order to transport the metal in and out of the protein.4 Smaller
ferritins (~240 kDa and 12 subunits) present in bacteria and archaea utilize iron to bind with
dioxygen or peroxide, protecting against damage toward DNA. In larger ferritins such as human
ferritin, iron initially interacts with dioxygen, shortening the distance between two ferrous ions
with a peroxo bridging linkage, which consequentially increases available iron storage.
Furthermore, with involvement of water and hydrogen peroxide, it can finally increase the iron
storage as Equation 1.3 described below.
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Figure 1.17: X-ray crystallography of apo-ferritin (PDB ID: 1AEW).

Equation 1.3
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Heme, Iron Cluster and Non-Heme Proteins

Many proteins and enzymes incorporate one or more iron atoms into their structures,
especially at the catalytic active sites. Iron-containing proteins can be classified into three main
groups including heme, iron-sulfur cluster and non-heme proteins, and among which non-heme
proteins are further divided into mononuclear and dinuclear proteins.4, 70
Heme protein contains and Fe2+/3+ ion in the center of a hydrophobic planar porphyrin
ring, coordinating to the porphyrin ring through four nitrogen atoms from the porphyrin ring. The
remaining two coordination sites tend to coordinate with various amino acid residues, depending
on the function of the proteins.71 A classic example is hemoglobin and myoglobin which have the
protoporphrin IX in their active sites (Figure 1.18). Myoglobin is a monomeric form of
hemoglobin that can bind O2 and delivers it to muscle tissues.4 Hemoglobin is a tetrameric protein
that binds with O2 in red blood cells. Both myoglobin and hemoglobin exist in oxy, deoxy and
oxidized met forms, and deoxy is known as the T-state (T stands for intense due to high spin
ferrous center) in which the Fe2+ porphyrin tends to pucker out of the plane. The oxy state is
known as the R state (R stands for relax). In the deoxy form, the fifth coordination site is
coordinated through the NƐ from a histidine, also called the proximal histidine. Upon O2 binding
to the iron center, it also form H-bonding with the nitrogen from the distal histidine, gaining
stabilization and adopting a bent geometry.72
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Figure 1.18:X-ray crystallography of O2 binding to all four hame moieties in hemoglobin (PDB
ID: 1GZX).
The second group of iron-containing protein is iron-sulfur cluster proteins which consists
of multiple iron and sulfur atoms linked together. They have crucial roles in efficient electron
transfer in photosynthesis and respiration.64 The ability of iron and sulfur to delocalize their
electron density allows iron-sulfur clusters to be very efficient in transferring electrons. A classic
example is ferredoxins, with various Fe-S clusters that control the transportation pathways in
many membrane-bound redox enzymes.4 Iron sulfur proteins contain sulfide linked to one, two,
three Fe ions which all have different oxidation states. Iron-sulfur clusters bind to the protein via
the side chains of cysteine. Common structures of iron-sulfur clusters contain a rhomboid cluster
([2Fe-2S]) consisting of two sulfur atoms linked to two iron atoms.73 All of the iron-sulfur
proteins transfer one electron at a time by changing ferric and ferrous redox states. Another
common iron-sulfur structure is a cubane form consisting of four iron and four sulfur atoms;
larger and more complex iron-sulfur clusters are observed in enzymes like nitrogenase and
hydrogenases with more metal ions present in the structure. A summary of the structures,
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oxidation states and spin states of iron-sulfur clusters is presented in Figure 1.19. Examples of
biological iron-sulfur clusters and their functions are summarized in Table 1.1.64
Table 1.1: Examples of iron-sulfur containing biological proteins.64
Examples

Function

Cluster type

Ferredoxins

Electron transfer

[2Fe-2S]; [3Fe-4S]; [4Fe-4S]

Rieske protein

Coupled electron and proton

[2Fe-2S]

Nitrogenase

transfer

[8Fe-7S]

Acetyl-CoA synthase

Substrate binding and

[Ni-4Fe-5S], Ni-Ni-[4Fe-4S]

Radical SAM enzymes

activation

[4Fe-4S]

Ferredoxins

Iron or cluster storage

[4Fe-4S]

Endonuclease III

Maintain structure integrity

[4Fe-4S]

Redox enzymes

[4Fe-4S]

MutY
FNR

Regulation of gene expression
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Figure 1.19:Structures, core oxidation states and spin states of x-ray crystallographically defined
iron-sulfur clusters.62
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Non heme proteins are a group of proteins containing at least one iron atom at their
catalytic active sites which interact with dioxygen, transferring one or both oxygen atoms from
dioxygen to the substrate. Depending on the number of iron atoms at their active sites, non-heme
dioxygenases are divided into two groups: mononuclear dioxygenases and dinuclear
dioxygenases.4
Mononuclear iron enzymes catalyze a variety of reactions in biological systems, including
the biodegradation of aromatic compounds, biosynthesis of antibiotics and metabolic pathways of
amino acids, fatty acids, and nucleic acids.74 Many of the mononuclear non heme iron enzymes
contain a ferrous metal center at their catalytic site which activates dioxygen for further reactions,
while in intradiol dioxygenases and lipoxygenases they both contain a ferric metal center.75
Unlike heme proteins which exhibit intense colors attributed to the

transition and can be

easily characterized by many spectroscopic methods, non-heme proteins provide a boarder array
of challenges for spectroscopic characterizations.76 The crystal structures of non-heme ferrous
center active sites showed that Fe2+ is coordinated to two histidine residues, one monodentate
carboxylate and two or three water molecules.74a Unlike heme proteins, which only have one open
coordination site, which allows dioxygen to bind to and activate. Due to the open coordination
sites on non heme ferrous proteins, they allow chemical exchanges to occur, such as cofactor or
substrate binding.
The two histidine and one carboxylate motif is found in many non-heme mononuclear
dioxygenases. For example, tyrosine hydroxylase (TyrH) is a non-heme protein that contains a
ferrous Fe2+ ion at its active site which catalyzes the conversion of L-tyrosine to L-dopa by
inserting an O atom from dioxygen and using ferrous iron and tetrahydrobiopterin as cofactors.77
The active site of TyrH coordination has a square pyramidal geometry with two histidines (His
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331 and His 336) and one glutamic acid (Glu376) coordinated to Fe2+.78 Another example is the
2,3-dihydroxybiphenyl 1,2-dioxygenase (BphC) which performs extradiol cleavage of 2,3dihydroxybipheny. The active site of BphC has a square pyramidal geometry with His-145 on the
axial site, and His-209 and Glu-230 on the basal plane.79 Isopenicillin N synthase (IPNS) is
another non-heme ferrous dioxygenase that contains 2-his-1-carboxylate motif. However, unlike
BphC and TryH which have glutamic acid as carboxylate donor, an aspartic acid is present in
IPNS. Moreover, a glutamic acid residue is also present as the fourth endogenous ligand. 80
Mononuclear non-heme protein can also utilize ferric iron at their active sites, including
protocatechuate 3,4 -dioxygenase and lipoxygenases. Protocatechuate 3,4-dioxygenase is an
intradiol catechol-cleaving enzyme (Figure 1.20) and lipoxygenases which catalyzes the
hydroperoxidation of lipids.76
The coordination environment of the active site of protocatechuate 2,3 and 3,4
dioxygenases are shown in Figure 1.21 and their mechanisms of each are shown in Figure 1.22
and Figure 1.23 respectively. Due to the difference in chemistry between ferric and ferrous ions,
the mechanism of dioxygen binding of each takes very different pathway (Figure 1.20). For 3,4
dioxygenase, the active site contains two histidines and one tyrosine coordinated to the ferric
center leaving open coordination sites on the metal to interact with substrates.
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Figure 1.20: Catalytic activity of ferrous and ferric protocatechuate dioxygenases.

Figure 1.21: Coordination environments of protocatechuate 2,3 (left) and 3,4 dioxygenases
(right).70
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Figure 1.22: Mechanism of 2,3 catechol dioxygenases.70

Figure 1.23: Mechanism of 3,4 catechol dioxygenases70

Dinuclear iron proteins contain two iron atoms at their active sites that bind and activate
dioxygen, such as hemerythrin (Hr), methane monooxygenases (MMO) and the B2 subunit of
ribonucleotide reductase (RRB2).81 In this section, O2-transporting hemerythrin and methane
monooxygenase will be briefly discussed.
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Hemerythrin is an oxygen transporter present in a few in-vertebrates, although the name
contains “heme,” the chemical structure does not contain a heme group—instead, the active sites
consist of two iron centers.4 Hemerythrin has a molecular mass about 108 kDa and composed of
13.5-kDa subunits.4 It cycles between deoxy and oxy forms. In deoxy form, both ferrous centers
are linked by hydroperoxide complex through the carboxylate moieties of glutamic acid and
aspartic acid.82 One of the ferrous centers is coordinated to three nitrogen atoms, each from three
different histidine residues, while the other ferrous center only coordinates with two histidines
leaving one empty coordination site.83 The dioxygen binding mode is shown in Figure 1.24. Met
form of hemerythrin can also be generated through irreversible oxidation where the only open
coordination site of the ferrous center can be occupied by an exogenous ligand like azide, which
is artificially in the study.84

Figure 1.24: Hemerythrin before and after O2 binding.84
Methane monooxygenases (MMO) is responsible for catalyzing the hydroxylation of
methane to methanol in metanotrophs, which are anaerobic prokaryotes that use methane as their
main carbon source for energy.85 Methane monooxygenase catalyzes methane oxidation pathway
by inserting an O atom from O2 into a stable C-H bonds of methane, with two reducing
equivalents from NAD(P)H, that break the O-O bond. Wherein, one oxygen atom is reduced to a
water molecule, while the second oxygen atom is incorporated into the final product methanol
35

(Equation 1.4).74b Other than oxidation of methane, MMO can also oxidize various other
hydrocarbons, including linear, branched, cyclic, saturated and unsaturated hydrocarbons up to 8
carbons.74b MMO is composed of three main domains, each of which are responsible for specific
activity, allowing substrate hydroxylation coupled to NADH oxidation. The three domains are a
dehydroxylase MMOH (245 kDa), reductase MMOR (40 kDa) and component B protein
(MMOB).85 The proposed mechanism of MMO is presented in Figure 1.25.
Equation 1.4
(

(

Figure 1.25: Proposed catalytic mechanism of MMO proteins.86
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Chapter 2 : Structure and Activity Relationship of Bacitracin
Complexes of Cu(II) and Fe(III)
Introduction
Introduction to Bacitracin

Bacitracin is a cyclic dodecapeptide metalloantibiotic from soil bacteria, Bacillus subtilis
and licheniformis. Bacitracin was first isolated in 1943 from the Basillus culture sample collected
from the wound of a seven-years-old-American patient, Margaret Tracy, hence the name.1 It is
mainly used against Gram-positive bacteria cocci and bacilli,1-2 including streptococcus and
clostridium diffcile; it can inhibit the growth of some Archaebacteria, for example, Halococcus
Methanobacterium, and Mathanococcus.1-3 In addition, it had also shown inhibition activity
toward Perkinsus marinus which causes high death rate in oysters due to the disease known as
perkinsosis, which causes degradation of oyster tissues.4 Bacitracin is one of the most produced
antibiotics worldwide; it is used extensively in livestock industry as additive to animal feed to
enhance overall health and prevent diseases.5 However, the European Union has banned the use of
bacitracin as a preventative antibiotic in animal feed since 1997, with the concern of antibiotics
resistance. As a result of the ban, later studies reported higher rates of sickness and death as well
as decline in overall health of farm animals indicating the significance of bacitracin in livestock
industry.6 Besides being used commonly in livestock industry, bacitracin is also used along with
neomycin, and polymycin in over-the-counter topical triple antibiotic such as Neosoporin® and
Polysporin®.7 Bacitracin can be considered safe when administrated through ingestion, since it
does not get absorbed very well by the gastrointestinal tract. However, bacitracin is nephrotoxic
and can damage kidney cells when prescribed systematically, thus it is usually not administrated
unless as a last resort antibiotic.8 The usage of antibiotics to treat infectious diseases started in the
early 1940s, and quickly followed by antibiotic resistance. Unfortunately, almost all antibiotics
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introduced have developed different levels of resistance toward them. As for bacitracin, although
around 60% of the bacteria have developed resistance toward it, there has been no new report on
the development of full resistance toward the bacteria.9

This could likely be attributed by

bacitracin’s unique structure and mode of action.
Structure and Biosynthesis of Bacitracin

Many peptides and polyketides biosynthesis follow the nonribosomal synthase pathway,
and are catalyzed through large clusters of peptide and ketide synthases. Bacitracin is produced by
soil bacteria, Bacillus subtilis and licheniformis, as a mixture of associated cogeners through a
nonchromosomal/nonribosomal pathway by a peptide synthase.1 The solid phase total synthesis of
bacitracin A1 was reported by Lee and Griffin in 1996. Bacitracin synthase ABC is responsible of
synthesizing bacitracin; it is a multi-enzyme complex consisting of BacA, BacB and BacC,
respectively with molecular weights of 598 kDa, 297 kDa, and 723 kDa.10 The congeners are very
similar in structure with the variation of substituted amino acids (Figure. 2.1). During the 1970s,
by using the counter current distribution (CCD) method, a crude bacitracin mixture was first
separated into several components, A, B, C, D, E and F.11 With the use of HPLC,12 fast atom
bombardment tandem mass spectrometry (FAB-MS) and electrospray ionization mass
spectroscopy (ESI-MS), about 30 different minor fragments were further identified and
analyzed.13 Among them, the major component bacitracin A1 exhibits the strongest antimicrobial
activity. A study using capillary electrophoresis showed that bacitracin contains more than 50
variations of peptides.14 Due to the complex congener mixture of bacitracin, scientists
encountered difficulty in determining the structure of the pure active major component, bacitracin
A1; it was not until twenty years after the discovery of bacitracin by Meleney and Johnson in 1943
that the structure of bacitracin A1 was proposed.1 Further spectroscopic, chemical and
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crystallographic methods were used to elucidate its cyclic dodecapeptide structure. The unique
cyclic heptapeptide structure of bacitracin A1 is attributed to the amide linkage between the Cterminus of Asn-12 and the side chain of Lys-6. Apart from its unique cyclic structure, bacitracin
A1 contains several unnatural amino acids, including four D-amino acids D-Orn-7, D-Glu-4, DPhe-9 and D-Asp-11, it also contains a thiazoline ring, forming from condensation of the carboxyl
moiety of Ile-1 and −SH moiety of Cys-2.15 This uncommon structure is likely protecting
bacitracin A1 from degradation by protease, and playing an important role in its strong
antibacterial activity and low antibiotic resistance. The first NMR spectrum of bacitracin A1 was
obtain in 1972,16 and with different 1D and 2D NMR methods, the structure of bacitracin A1 was
first elucidated in the early 1990s; the results indicated a tail formed from Ile-1 to Glu-4 bending
toward the seven-membered ring, which brings His-10, Glu-4 and the thiazoline ring close to each
other, creating a potential metal binding site.17 The peptide sequences of bacitracin B1, B2 and B3
are mostly similar to bacitracin A1 when replacing Ile-1, Ile-5 and Ile-8 respectively with a valine.
Components of bacitracin A and B together are responsible for almost 90% of the biological
activity, while bacitracin A2 shows little activity. Bacitracin F is the biologically inactive,
oxidized product of bacitracin A1, through oxidative conversion of amino methylene-thiazoline
groups to keto-thiazole groups.9 It is suspected that bacitracin F is responsible for the nephrotoxic
property. The summary of the congener structures and molecular weighs are presented in Figure
2.2 and Table 2.1 below.9 Bacitracin’s mode of action for antimicrobial activity is through
inhibition of the biosynthesis of peptidoglycan, which is necessary for cell wall synthesis in most
Gram-positive bacterial.18 The metallo-bacitracin was demonstrated to bind to long chain C55isoprenol pyrophosphate tightly, where the binding constant Kf is 1.05× 10–6 M–1.19 The binding
prevents the hydrolysis of the complex into monophosphate, a compound essential for cell wall

47

synthesis. With limited amounts of monophosphate binding to UDP-MurNAc-pentapeptide to
initial the biosynthesis of cell wall, the inhibition successfully occurs (Figure 2.3).9

Figure 2.1: Schematic structure of bacitracin congeners.9
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Table 2.1: Bacitracin congeners and their molecular weights, corresponding to Figure 2.2.9
Congener

M. W.

X

Y

R

A1

1422.7

L-Ile

L-Ile

R1

A2

1422.7

L-Ile

L-Ile

R2

B1

1408.7

L-Ile

L-Ile

R3

B2

1408.7

L-Val

L-Ile

R1

B3

1408.7

L-Ile

L-Val

R1

D1

1394.6

L-Val

L-Ile

R3

D2

1394.6

L-Ile

L-Val

R3

D3

1394.6

L-Val

L-Val

R1

F

1419.6

L-Ile

L-Ile

R4

Desamido

1423.6

L-Ile

L-Ile

R1

Figure 2.2: Pathway of cell wall synthesis and bacitracin inhibition.9
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Metal binding to Bacitracin

Bacitracin has the ability to coordinate with several transition metal ions, listed as follows
with their metal binding affinity constants: Cu2+ (6460 M-1), Ni2+ (1381 M-1), Co2+ (214.0 M-1),
Zn2+ (74.36 M-1) and Mn2+ (weak).20 Bacitracin is a metalloantibiotic which becomes bioactive
when coordinating with divalent metals. Commonly used drugs including amphomycin,
actinomycin, cephalosporin, gramicidin, polymyxin and vancomycin along with bacitracin can be
categorized as “bio-active” peptides-based antibiotics. This group of compounds often contains
unique motifs such as unusual amino acids, cyclic structures, D-amino acids, lipid tails and sugar
moiety.21 Upon Cu(II) binding, prevuiys studies showed Cu(II) binding to bacitracin and
performed catechol oxidation following pre-equilibrium enzyme like kinetics.22 Cu(II)-bacitracin
complex showed inhibition toward Neurospora crassa mold growth.23 Zn(II)-Bacitracin complex
is one of the active ingredients in Neosporin, the widely-used triple antibiotic ointment. Zn(II)bacitracinis also added to animal feeds in order to improve health, increase weight, and prevent
diseases.
The first NMR spectrum of bacitracin was acquired in 1972 by Chapman and Golden,16
later followed by 2D NMR studies in the 1990s showed the tail, starting from Ile-1 and ending at
Glu-4, bending towards the aromatic rings.17c This brings Glu4 and the thiazoline ring close to
His10, forming a metal binding pocket.17c Previous EPR study on Cu2+-bacitracin complex at pH
5.2 showed tetragonal distorted geometry with two coordinated nitrogen and two coordinated
oxygen atoms. Later EPR results showed distorted octahedral coordination for the Cu2+-bacitracin
complex, indicating that Asp-11, His-10, Glu-4 and nitrogen on the thiazoline ring coordinate
with the metal ion.24 The structure activity relationship of the cobalt (II) complex of bacitracin
and its congeners were elucidated through various 1D and 2D NMR techniques. The structure of
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Co2+-bacitracin was assigned by the use of hyperfine-shifted 1H NMR, and the results indicated
that Co2+ coordinates to bacitracin through the thiazoline ring, Nε on the imidazole ring from His10 and the carboxylate from Glu4.25 The results also showed that upon cobalt (II) binding, a
hydrophobic pocket was formed from Ile-5, Ile-8 and D-Phe-9. This hydrophobic pocket is
important for bacitracin binding to C55-isoprenol phosphate in addition to its antimicrobial
activity. In a modeling study, a C15-isoprenoid farnesyl pyrophosphate was used as the chemical
model for probing the metallobacitracin interactions with lipoid pyrophosphate. The results show
the lipid pyrophosphate situated into the hydrophobic topic.22

Figure 2.3: Farnesyl pyrophosphate-bound metallobacitracin resolved through mechanics
calculations (Pink: before farnesyl PP binding; blue: after farnesyl PP binding).22
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Flavonoids

Flavonoids are a group of secondary metabolites from plants and fungi, and are generally
found in various kinds of fruits and vegetables; and are also found in nuts, grains, seeds, wine
(especially red wine) and tea. Flavonoids typically have a general chemical structure consisting of
a 15-carbon skeleton mode with two phenyl rings (labeled as A and B), as well as a heterocyclic
ring (labeled as C) in the middle (Figure 2.4). There are over 5000 naturally occurring flavonoids
that have been identified and characterized; these flavonoid compounds can further be divided
into five main subgroups based on their structure; anthoxanthins (flavone and flavonol),
flavanones, flavone, flavanonols and flavan-3-ol (Figure 2.5). Other minor flavonoid subgroups
contain coumarins, aurones, chalcones and biflavones.26

Figure 2.4: Typical flavonoid structure.
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Figure 2.5: Typical structures of the five flavonoid subgroups.

Flavonoids are responsible for performing many important biological functions in plants.
For example, flavonoids cause the red, violet and yellow color pigments in flower petals, allowing
flowers to attract insects and animals, spreading pollen efficiently in the process.27 Flavonoids can
perform various biological functions due to interactions with enzymes; for example,

they

participate in the signaling pathway, have the ability to coordinate with metal ions while also
scavenging free radicals.28 Flavonoids can be involved in both gene regulation and growth
metabolism. For example, some flavonoids inhibit the exocytosis of auxin indolyl acetic acid,29
while others can also promote the growth and development of plants by performing antimicrobial
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and antifungal activity. Flavonoids are advantageous for human health; they not only have
neuroprotective properties, but can act as an antibiotic, antiviral, anticancer, antiallergenic,
antiheptatotoxic, anti-inflammatory and antiatherogenic with low toxicity.30 There are many
studies which show the therapeutic ability of flavonoids toward HIV viral load, which potentially
widens the potential treatment toward AIDS.31 Due to the neuroprotective property of flavonoids,
they also target against certain neurodegenerative diseases such as Huntington’s and Alzheimer’s
disease.32 The wide array of functional groups on flavonoid allow it to perform many beneficial
biological activities, potentially serving as an ideal template for drug design.
Among all properties flavonoids possess, their ability to coordinate with various metal
ions is especially important. The phenolic hydroxyl moiety in flavonoids are usually involved in
metal binding, where upon deportonation of the hydroxyl group, the flavonoid acts as a Lewis
base, donating electrons to coordinate with metal ions (generally considered as Lewis acids).33
Various metallo-flavonoid complexes were investigated and characterized, and the metalloflavonoid complexes can show different biological activities such as antioxidant,34 DNA
binding,35 SOD mimicking36 and inhibition toward peroxidation.37 The strong affinity toward
various metals also opens the opportunity to utilize flavonoids in the analytical field. For
example, quercetin can bind to aluminum ions—forming stable complex—and can be used for
treatment of aluminum overload in diet, as well as use in spectroscopic methods for determining
aluminum concentration with the use of HPLC.38
Catechins and analogues are a group of closely-related flavonoids categorized under the
subgroup flavan-3-ol, also known as flavanols (Figure 2.6). The chemical name catechin was
derived from catechu, the extract of acacia trees, Mimosa catechu.39 The structure of catechin
consists of two benzene rings, with two hydroxyl moieties on each ring, as well as a dihydropyran
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heterocycle with a hydroxyl moiety. The A ring resembles a resorcinol moiety, while the B ring
resembles catechol moiety. There are different analogues of catechins including (–)-catechin, (+)catechin, (+)-epicatechin and (–)-epigallocatechin gallate; among these, (+)-catechin and (–)epicatechin are the most common and extensively studied stereoisomers. Catechin (Ct),
epicatechin (Epi) and epigallocatechin gallate (EGCG) can be found in various fruits and
vegetables, and are most abundant in cocoa and teas—especially green tea.40 The major catechin
and derivatives in green tea include EGCG, (–)-epigallocatechin, (–)-epicatechin gallate and (–)epicatechin, and EGCG accounts for 50-80% of the 200-300 mg of catechins in a cup of brewed
green tea.41 EGCG is studied extensively and was shown to exhibit beneficial activities such as
acting as an antioxidant, as well as treatment for diabetes,42 Parkinson’s disease, Alzheimer’s
disease and some cardiovascular diseases.41, 43 These closely related phytochemicals all are known
to be potent antioxidants toward redox systems. For example, Yilmaz and Toledo compared
different phenolic compounds in terms of their inhibition activities against peroxyl radicals
generated by AAPH. The results indicate catechin has the highest peroxyl radical scavenging
capacity in the flavanols group.44 Due to their strong antioxidative activity and some with ability
to pass through blood brain membrane,45 these compounds could potentially provide treatment for
neurodegenerative diseases.46
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Figure 2.6: Chemical structure of different types of catechins.
Quercetin is one of the most common and prominent flavonols. The name quercetin is
derived from the Latin words quercetum and quercus, which stand for oak forest and oak
respectively from which it was first isolated. Quercetin can be found ubiquitously in various food
sources such as vegetables, fruits, teas (10-25 mg/l),47 cocoa, and wines (270 mg/l).48 Red kidney
beans contain the highest amount of quercetin (603 ± 307 mg/100g) among all food groups.49
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Quercetin was also demonstrated to be able to pass through blood brain barrel.45 Previous
studiesof quercetin showed ability to inhibit the oxidative activity generated by Cu2+-AβAmyloid.46b, 50
Like many other flavonoids, quercetin can coordinate with various metal ions. There are
three potential metal binding sites in quercetin: the β-ketophenolate on ring A, the α-ketoenolate
on ring B and the catechol moiety on ring C (Figure 2.7). Using Co(II) as a probe, the
paramagnetic NMR results indicated that quercetin coordinates with Co(II) through the αketoenolate on ring B.46b Besides being an antioxidant, quercetin was extensively studied and
shown to exhibit various biological activities.51 For examples, quercetin can suppress the growth
of drug-resistant spheres in oral cancer cells.52 Quercetin also decreases the expression of the Creactive protein in humans with associated cardiovascular risks; alternatively it has antiproliferative and anti-inflammatory properties in humans, vitro and vivo studies.53

Figure 2.7: Chemical structure of quercetin.
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The structure and activity relationship of metal ions with different flavonoids was studied
extensively for potential medical and commercial purposes.21,
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However, in spite of all the

extensive studies, there is very little focus on how flavonoids interact with other metallocompounds in the soil system. This project provides an opportunity to gain detail understandings
of the micro-ecology in soil. Most soils are rich in transition metals and various phytochemicals
such as flavonoids and carotenoids. Many of these phytochemicals, like quercetin, contain
potential metal binding sites; once complexed with metals, through the metal center, it may
interact with other chemicals in the soil, such as bacitracin. There are countless bacteria and
organisms present in soil, and their derivatives can potentially interact with metal ions near them,
given the suitable condition. If they do encounter each other, what kind of chemistry are they
doing? Are there balancing forces among all photochemicals and microbiological chemicals to
help maintain the overall eco balance? Do flavonoids protect plants from free radicals and
oxidative stressed generated by metal ions or metallo-complexes in soil?

By asking these

questions, it provides us the opportunity to gain detailed understanding of the molecular dynamic
in the soil ecosystem.
In the first part of this chapter, interactions of several flavonoids with Cu(II)-bacitracin
will be studied by using spectroscopic and kinetic methods. The second part of the chapter
focuses on iron (III) binding to bacitracin and its potential chemical interactions with flavonoids.
The purpose of this project is to gain insight into the micro-ecology ofsoil system by directly
looking at the chemical interactions of flavonoids with copper-bacitracin.
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Material and Methods
All reagents and solvents were purchased from Sigma-Aldrich and Fisher. Aqueous
solutions were prepared from 18 MΩ deionized water. Ligand binding and kinetic measurements
were performed on a Varian Cary50 Bio UV-vis spectrometer equipped with a temperature
controller.
Kinetics and Optical by UV-Vis

All kinetic experiments of Cu2+-Bc complex (1 to 2 μM) were done in 100 mM of HEPES
buffer solution at pH 7.0 and 25 ºC. All kinetics experiments involving Fe3+-Bc complex (10 to
200 μM) were done in a mixture solution of 90% methanol and 10% 200 mM HEPES buffer at
pH 7.0 and 25 ºC.
Catechin, epicatechin and epigallocatechin gallate (EGCG) studies: Catechin (Ct),
epicatechin (Epi) and epigallocatechin gallate (EGCG) were dissolved in methanol; the
concentration of their stock solutions were determined by UV-vis absorptions in D.I. water (Ct
and epicatechin: Ɛ276 = 10232 M–1 cm–1 and EGCG Ɛ274 nm = 8400 M–1 cm–1).55 For oxidation
experiments, Cu2+-Bc were incubated with different amounts of substrates (Ct, Epi and EGCG) in
100 mM of HEPES buffer solution at pH 7.0 and 25 ºC. In the peroxide-saturation experiment, 1
mM of substrates (catechin and epicatechin) and Cu2+-Bc were incubated in 100 mM of HEPES
buffer solution at pH 7.0 and 25 ºC. The changes in absorption of their corresponding oxidized
product formation were measured as a function of time. The molar absorptivity of their
corresponding MBTH-ortho-quinones for catechin, epicatechin, and EGCG are Ɛ459 nm = 17230,
Ɛ465 nm = 18950 and EGCG, and Ɛ465 nm = 7665 M–1 cm–1, respectively.56
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Quercetin inhibition toward catechol oxidation by Cu2+-Bc study: An amount of 1 to 2 μM
of Cu2+-Bc wasincubated with 2-mM catechol with increasing amounts of quercetin in 100 mM
HEPES buffer solution at 25 ºC. The oxidized MBTH/ortho-quinone formation was measured at
500 nm (catechol/MBTH = 32500 M–1 cm–1) as the change in absorption as a function of time.
Optical study of quercetin binding to 25 μM of free metals and metallo-bacitracin was done in
DMSO with 2 equivalents of triethylamine (TEA) in order to fully deprotonate the potential metal
binding site.
Cu(II)-Bc complex study: 1 to 2 μM of Cu(II)-Bc was incubated with 2 mM catechol with
increasing amounts of quercetin in 100 mM HEPES buffer solution at 25 ºC. The oxidized
MBTH/quinone formation was measured at 500 nm (catechol/MBTH = 32500 M–1 cm–1) as the
change in absorption as a function of time.
Fe(III)-Bc complex study: UV optical binding studies were done by titrating increasing
amount of bacitracin with 50 μM Fe3+ (FeCl3 as the source) in methanol. The quercetin binding to
Fe+3 and Fe3+-Bc studies were done in methanol. Kinetic reaction were done in 90/10
methanol/200 mM HEPES buffer at pH 7.0 at 25ºC.
Resonance Raman Spectroscopy

All resonance Raman experiments were performed by using a confocal Raman
microscopy (LabRam Horiba Jovin Yvon) equipped with a notch Rayleigh rejection filter, a 600
grooves/mm diffraction grating and a cooled CCD detector. For all experiments, an excitation
wavelength of 526 nm from an Argon and Krypton laser (Coherent, Innova 70C series) was
applied. The exposure time was 10 s and the number of accumulations was 10. Each 1 mL sample
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was dissolved in methanol, and the resonance Raman spectra were measured in the range of 200
to 1700 cm−1.
NMR Spectroscopy

All NMR spectrums were collected on a Varian Unity INOVA 600spectrometer in
University of South Florida Interdisciplinary NMR Facility. The data were recorded with either a
triple resonance probe or broad band width probe in the INOVA 600.
Co-Bc-Qr ternary complex: All chemicals were dissolved in d6-DMSO. Co(II)-bacitracin
and Co(II)-quercetin were prepared by direct addition of one equivalent of Co 2+ (from CoCl2) to
bacitracin and quercetin with two equivalents of triethylamine. The ternary complex was prepared
by addition of one equivalent of bacitracin to 8 mM Co(II)-quercetin in d6-DMSO with two
equivalents of triethylamine.
Fe-Bc complex: A 8 mM 500 μL 1:1 Fe3+-Bc complex was prepared by direct addition of
one equivalent of Fe3+ to bacitracin in methanol. No triethylamine was added. The sample was
collected in a 600 MHz field by applying a solvent suppressing technique, Super-WEFT pulse
sequence (τ1-180°-τ2-90°-FID).

Results and Discussion
Catechin, Epicatechin and Epigallocatechin Gallate (EGCG) Interaction with Cu(II)- Bacitracin
Complex

Within the soil system, metal ions, flavonoids and soil-derived biomolecules exist
ubiquitously, and they can chemically interact with each other through their metal centers.
Bacitracin is an antibiotic, produced by soil bacteria of the Bacillus genes, such as Bacillus

61

subtilis, which can bind to various transition metal ions.9 Bacitracin has been previously
demonstrated to bind Cu(II) and exhibit pre-equilibrium enzyme-like oxidation catalysis.22
Catechin and epicatechin are stereoisomers of each other and contain a catechol moiety on each.
Our previous study showed Cu(II)-bacitracin complex can oxidized catechol into o-quinone
product efficiently in aqueous systems.22 In this study, the aim is to check whether Cu(II)-Bc
complex can interact and oxidize catechin and analogues/derivatives including (+)-catechin, (–)epicatechin and (–)-epigallocatechin gallate (EGCG), and differentiate the two stereoisomers
catechin and epicatechin based on kinetics measurements.
In order to check whether catechin (Ct), epicatechin (Epi) and epigallocatechin gallate
(EGCG) interact with Cu(II)-Bc complex; standard catechol oxidation assay were used to evaluate
the activities.22 The oxidation chemistry of Cu(II)-Bc were studied by using catechin, epicatechin
and EGCG as substrates. Different concentrations of substrates were used ranging from 0.1~4.8
mM and MBTH was used to trap the oxidized o-quinone product in 100 mM HEPES buffer
solution at pH 7.0 at 25 ºC. The oxidized o-quinone products couple with MBTH, to form the
pink MBTH/o-quinone adducts appeared around 459 to 465 nm. The changes in absorption were
measured as a function of time, then converted to rates by using their corresponding molar
absorptivity (catechin: Ɛ459 nm = 17230, epicatechin: Ɛ465 nm = 18950 and EGCG: Ɛ465 nm = 7665 M–
1

cm–1).56
The results of catechin, epicatechin and EGCG oxidations by 2 μM Cu(II)-Bc complex are

shown in Figure 2.8. All three substrates were efficiently oxidized; the oxidation rates increased
initially, eventually reaching plateau, suggesting that the reactions followed pre-equilibrium
enzyme like kinetics. The reaction is described in Equation 2.1, where S stands for catechin,
epicatechin or EGCG, assuming the concentration of substrate (S) is in excess compared to the
62

Cu(II)-Bc-S (ES complex) (Equation 2.1). The data were fit to Equation 2.2, while the apparent
dissociation rates constant (Km) and maximum reaction rates (Vmax) were obtained, where v0 was
the measured velocity. The catalytic first-order rate constant (kcat) can be obtained from Vmax
(Equation 2.2), where Km is the apparent dissociation constant of the intermediate (Cu2+-Bc)Substrate complex (Table 2.1).
Equation 2.1

Equation 2.2

Equation 2.3

(+)-catechin and (–)-epicatechin are stereoisomers of each other, each having the same
chemical formula, weigh and UV-vis optical absorption. Under identical conditions, catechin has
a higher kcat value (first order rate constant) of 0.006 s–1, whereas epicatechin it is 0.003 s–1. The
apparent dissociation constant (Km) value of epicatechin is 0.43 mM, while for catechin it is 1.19
mM. The smaller Km value of epicatechin indicates Cu(II)-Bc-epicatechin intermediate is more
stable and does not go through Cu(II)-Bc-epicatechin complex dissociation easily compared to
Cu(II)-Bc-catechin complex. The ratio of kcat/Km describes how efficient the complex is at
catalyzing the reactions. The kcat/Km of epicatechin is 0.0069 mM–1 s–1, while for catechin it is
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0.005 mM–1 s–1. The results from Figure 2.8 showed that Cu(II)-Bc complex oxidized EGCG
much faster than catechin and epicatechin; the kcat of EGCG is 1.0×10‒4 s‒1, Km is 2.62 mM and
kcat/Km is 0.02 mM–1 s–1. EGCG is almost 3-fold more efficient at producing o-quinones
compared to catechin and epicatechin—this is mostly due to the fact that EGCG has more sites to
be oxidized by Cu(II)-Bc.
Catechin, epicatechin and EGCG oxidation by 2 uM CuBc in 100 mM HEPES pH 7

Catechin
Epicatechin
EGCG

6e-5

Rate (mM/s)

5e-5

4e-5

3e-5

2e-5

1e-5

0
0

1

2

3

[subsstrate] mM

Figure 2.8: Catechin, epicatechin and EGCG oxidation by 2 μM of Cu(II)-Bc complex in 100
mM HEPES buffer at pH 7.0.
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Table 2.2: Catalytic parameters of different substrates oxidation by 2 μM Cu(II)-Bc complex in
100 mM HEPES buffer at pH 7.0.

Vmax (mM/s)

Catechin/MBTH

Epicatechin/MBTH

EGCG/MBTH

(Rs=0.9961)

(Rs=0.9959)

(Rs=0.9980)

(1.20±.08)×10

–5

(5.98±0.24) ×10

–6

–4

(1.0±0.01)×10

Km (mM)

1.19±0.19

0.43±0.06

2.62±0.39

kcat (s–1)

0.0060

0.0030

0.05

kcat/Km (mM–1 s–1)

0.005

0.0069

0.02

Upon catechol binding to the Cu(II) center, catechol was oxidized and releasing the first oquinone, and the Cu(II) center is then reduced to Cu(I). Under aerobic condition, after reduction
of Cu center from Cu(II) to Cu(I), it allows dioxygen binding to the copper center, forming three
possible intermediates including Cu(III)-peroxo, Cu(II)-hyroperoxo and Cu(II)-superoxo
complexes.22 Previous studies proposed that it is most likely the end-on Cu(II)-O2 or Cu(II)-OOH
that is the intermediate. In contracts to dioxygen, which only binds to Cu(I) center, hydrogen
peroxide can directly bind to Cu(II) center through a side-on mode forming Cu(II)-Bc-O22–
intermediate.9, 22
Hydrogen peroxide is a strong oxidizing agent and can participate in the catechol
oxidation by Cu(II)-Bc.22 Based upon kinetics measurement from (+)-catechin and (–)-epicatechin
oxidation by Cu(II)-Bc complex, the complex showed strong ability to differentiate between two
stereoisomers. To check whether or not hydrogen peroxide can participate in the redox cycle of
Cu(II)-Bc with catechin and epicatechin, increasing amounts of hydrogen peroxide were added to
2.0 μM Cu(II)-Bc and 1.0 mM substrate (Ct or Epi) in 100 mM HEPES buffer at pH 7.0 and 25
65

ºC (Figure 2.9). As the concentration of hydrogen peroxide increased, the oxidation rates
increased and eventually reached plateaued at around 15 mM hydrogen peroxide. This
phenomenon indicated hydrogen peroxide interacts with Cu(II) center and mimicked peroxidase
activity. The results were fit to Equation 2.4 and the catalytic parameters are summarized in Table
2.2.
Equation 2.4

From Equation 2.4, the apparent binding constants of catechin and epicatechin are 5.30 ±
1.07 mM and 4.12 ± 0.93 mM respectively, with the resulting kcat of catechin and epicatechin
being 0.0055 s–1 and 0.0094 s–1 respectively. With increasing amounts of hydrogen peroxide, the
catalytic rates eventually reached plateaued, indicating pre-equilibrium enzyme like kinetics.
From the kcat/Km values, epicatechin is more efficient at performing peroxidation than Cu(II)-Bc
complex with the presence of another substrate (catechin or epicatechin).
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peroxide saturation of 2uM CuBc
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Figure 2.9: Different amounts of hydrogen peroxide added to 2 μM of Cu(II)-Bc and 1.0 mM of
substrate (catechin and epicatechin) in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
Table 2.3: Peroxidation catalytic parameters of catechin and epicatechin by 2 μM Cu(II)-Bc
complex with 1.0 mM of substrate (catechin and epicatechin) in 100 mM HEPES buffer at pH 7.0
and 25 ºC.

Vmax (mM/s)

Catechin

Epicatechin

(Rs=0.9938)

(Rs=0.9917)

(1.09±0.05) ×10

–5

(1.87±0.11) ×10

Km (mM)

5.30±1.07

4.12±0.93

kcat (s–1)

0.0055

0.0094

kcat/Km (mM–1 s–1)

0.0010

0.0023

–5

Catalytic activities of catechin and epicatechin oxidation by Cu(II)-Bc with saturating
amount of hydrogen peroxide were checked. In Figure 2.10, hydrogen peroxide concentration was
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fixed at 10 mM amount, with increasing amounts of catechin or epicatechin. The results are fit to
Equation 2.2 and the catalytic parameters are summarized in Table 2.3. The kcat values of both
catechin and epicatechin are 0.013 s–1, while the apparent binding constant (Km) for Cu(II)-Bcepicatechin (0.31 ± 0.11 mM) is three-fold lower than that of Cu(II)-Bc-catechin (0.98 ± 0.24
mM), indicating a more stable intermediate, resulting in a higher kcat /Km (0.041 mM–1 s–1 for
epicatechin and 0.013 mM–1 s–1 for catechin). The Km values of catechin and epicatechin without
hydrogen peroxide were both higher than the ones with hydrogen peroxide, and this indicated that
the presence of hydrogen peroxide enhanced the binding of catechin and epicatechin to Cu(II)-Bc.
Catechin and epicatechin oxidation by 2uM CuBc with 10mM peroxide in 100mM HEPES pH 7
3e-5
catechin
epicatechin
3e-5

Rate(mM/s)

2e-5

2e-5
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5e-6
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0

1
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Figure 2.10: Catechin and epicatechin oxidation by 2 μM Cu(II)-Bc complex with 10 mM H2O2
in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Table 2.4: Catalytic parameters of catechin and epicatechin oxidation by 2 μM Cu(II)-Bc
complex with 10 mM H2O2 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
Catechin (Rs=0.9895)

Epicatechin (Rs=0.9665)

Vmax (mM/s)

2.61×10–5

2.53×10–5

Km (mM)

0.98±0.24

0.31±0.11

kcat (s–1)

0.013

0.013

kcat/Km (mM–1 s–1)

0.013

0.041

Catechin and epicatechin are stereoisomers of each other and usually it is hard to
differentiate between them. From this study, both catechin and epicatechin go through oxidation
with and without the presence of hydrogen peroxide, mimicking catechol oxidase activity.
Furthermore, by using the catalytic parameters kcat and Km from kinetics results, Cu (II)-Bc
complex showed selectivity between the two stereoisomers catechin and epicatechin (Equation
2.5).57
Equation 2.5
𝑅% =

𝑐𝑎𝑡

𝑐𝑎𝑡

𝑐𝑎𝑡

𝑝𝑖

𝑐𝑎𝑡

𝑐𝑎𝑡 + ( 𝑐𝑎𝑡

) 𝑝𝑖

× 100%

By applying Equation 2.5, the stereoselectivity of Cu(II)-Bc complex toward epicatechin
and catechin in air is 16%, increasing to higher selectivity in the presence of hydrogen peroxide,
where the stereoselectivity is 52%.
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To conclude, Cu(II)-Bc complexes has veen demonstrated to efficiently oxidize catechin,
epicatechin and epigallocatechin gallate—following pre-equilibrium enzyme-like kinetics.
Among which, EGCG has a first order rate constant 8-fold higher than catechin and 16-fold
higher than epicatechin, due to more available sites to be oxidized. With the presence of hydrogen
peroxide, the apparent dissociation constants (Km) of both Cu(II)-Bc-Epi complex and Cu(II)-BcCt decreased, indicating that the presence of hydrogen peroxide promotes substrate binding to
Cu(II)-Bc complex. Compared to catechin, with and without the presence of hydrogen peroxide,
epicatechin has a smaller apparent dissociation constant. Moreover, by using kinetics
measurement, Cu(II)-Bc complex can distinguish between the stereoisomers of epicatechin and
catechin ,showing a 3-fold difference in their oxidation rates in the presence of hydrogen
peroxide.
Quercetin Inhibition Against Oxidation Activity of Cu(II)-Bacitracin Complex

Quercetin, 3, 5, 7, 3', 4'-pentahydroxyflavone, is a flavonoid that originated from oak trees
and is found in many fruits, vegetables, grains and leaves. It is one of the most extensively studied
flavonoids among many that exhibit antioxidant activity. It is considered as a potent free radial
scavenger mostly attributed to its ability to coordinate with metal ions.46b Previous study showed
quercetin inhibits competitively toward the oxidation of catecholamine neurotransmitter
dopamine by Cu(II)-beta amyloid complexes.46b The paramagnetic NMR studied using Yb3+ and
Co2+ suggested that quercetin bind to metal via the α-ketenolate moiety.46b, 50
The aim of this project is to investigate the chemical interactions between quercetin and
Cu(II)-Bc. Cu(II)-Bc was demonstrated to catalyze catechol oxidation with and without the
presence of hydrogen peroxide which can efficiently generated significant amounts of oxidative
stress.22 With accumulated amounts of reactive oxygen species (ROS) in the soil environment, the
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ROS pose as threats toward neighboring plants, microbes and organisms. Similar concept as the
catechin and epicatechin study, this is another approach of looking at the mirco-ecology of soil
system by checking the chemical interactions of quercetin and Cu(II)-Bc complex.
The UV electronic transition all traces were monitored through the range of 200 to 600 nm
in DMSO with two equivalents of triethylamines (TEA) to ensure full-deprotonation for optimal
metal binding. The UV electronic transition spectrum of apo-quercetin (solid line in Figure. 2.11)
has two characteristic absorptions: one around 300 nm (representing the benzoyl ring β-ketophenolate moiety) and another one at 380 nm (representing cinnamoyl ring: catechol and αketoenolate moieties).38a Upon addition of one equivalent of Cu2+ and Co2+ to quercetin, a new
absorption band appears around 450 nm and slight decrease in the absorption around 380 nm,
indicating metal directly interacts with quercetin. Upon Cu2+-Bc and Co2+-Bc complexes addition
to quercetin, a less intense absorption around 450 nm appeared, suggesting weaker quercetin
binding to metallobacitracins than to free metal ions.
Metal and metal complex titration to 25 uM quercetin in DMSO with 2eq TEA

Quercetin
Quercetin + 1eq Co(II)
Quercetin + 1eq Co(II)-Bc
Quercetin + 1eq Cu(II)-Bc
Quercetin + 1eq Cu(II)

molar absotivity (cm -1 M-1)

30000
25000
20000
15000
10000
5000
0
300

400
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nm

Figure 2.11: One equivalent of Co(II), Co(II)-Bc, Cu(II) and Cu(II)-Bc addition to 25 μM of
quercetin in DMSO at 25 ºC with 2 equivalents of TEA.
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Cu(II)-Bc complex undergoes DTBC oxidation exhibiting pre-equilibrium enzyme like kinetics
with and without the presence of hydrogen peroxide, providing kcat values of 0.38 s–1 and
respectively.22 In this study, catechol was used as the substrate for oxidation chemistry catalyzed
by Cu(II)-Bc complex. In Figure 2.12, using catechol as the substrate, Cu(II)-Bc complex
exhibited pre-equilibrium enzyme like kinetics with and without the presence of hydrogen
peroxide and can be described as Equation 2.6, and the data were fit to Equation 2.7 providing kcat
values of 0.004 s–1 and 0.04 s–1 respectively (Table 2.5). Hydrogen peroxide activity saturation
was shown in Figure 2.13 and Table 2.6.
Equation 2.6

Equation 2.7
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1 uM Cu(II)-Bc with 10 mM peroxide
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Figure 2.12: Catechol oxidation by Cu(II)-Bc with and without 10 mM hydrogen peroxide in 100
mM HEPES buffer at pH 7.0 at 25 ºC.

Table 2.5: Catalytic parameters of catechol oxidation by Cu(II)-Bc with and without 10 mM
hydrogen peroxide in 100 mM HEPES buffer at pH 7.0 at 25 ºC.

Vmax (mM/s)

2 μM Cu(II)-Bc with

1 μM Cu(II)-Bc with

no peroxide

10 mM peroxide

(Rs=0.9999)

(Rs=0.9936)

(9.09±0.20) ×10

–6

(4.12±1.12) ×10

Km (mM)

3.88±0.13

6.11±2.50

kcat (s–1)

0.004

0.04

kcat/Km (mM–1 s–1)

0.001

0.006
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Peroxide titration to 2mM catechol oxidation by 2uM Cu(II)-Bc in 100mM HEPES pH 7
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Figure 2.13: Peroxide saturation of 2 mM catechol oxidation by 2 μM of Cu(II)-Bc in 100 mM
HEPES buffer at pH 7.0 at 25 ºC.

Table 2.6: Catalytic parameters of hydrogen peroxide saturation of 2 mM catechol oxidation by 2
μM of Cu(II)-Bc in 100 mM HEPES buffer at pH 7.0 at 25 ºC.
2 μM Cu(II)-Bc with
2 mM catechol
(Rs=0.9936)
Vmax (mM/s)

(1.22±0.05) ×10

Km (mM)

2.65±0.53

kcat (s–1)

0.006

kcat/Km (mM–1 s–1)

0.002
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To check if quercetin interact with Cu(II)-Bc complex by inhibiting the metal mediated
redox reaction with and without the presence of hydrogen peroxide, increasing amounts of
quercetin were added to 2 mM catechol and 2 μM Cu(II)-Bc in 100 mM HEPES buffer at pH 7.0
at 25 ºC (Figure 2.14 and 2.15). The pinkish oxidized o-quinone/MBTH adducts showed up at
500 nm and the change in absorption was measured as a function of time.
Direct titration of quercetin to 2mM catechol oxidation by 2uM CuBc without peroxie
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Figure 2.14: Direct titration of quercetin to 2 mM catechol oxidation by 2 μM Cu(II)-Bc in 100
mM HEPES buffer at pH 7.0 at 25 ºC (Rs value = 0.9975).
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Direct titration of quercetin to 2mM catechol by 1uM CuBc with 10mM peroxide
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Figure 2.15: Direct titration of quercetin to 2 mM catechol oxidation by 1 μM Cu(II)-Bc with 10
mM H2O2 in 100 mM HEPES buffer at pH 7.0 at 25 ºC.

To determine the inhibition pattern of quercetin toward catechol oxidation by Cu(II)-Bc,
different concentrations of quercetin were mixed with 1 μM Cu(II)-Bc at various concentrations
of catechol (Figure 2.16). In all sets of concentration of quercetin, the data showed initial
increases in rate with increasing amounts of catechol, and eventually reached plateau. This pattern
indicates the system follows pre-equilibrium enzyme like kinetics, which is consistent with
previous catechol oxidation data. From Table 2.6, all four Vmax values remained similar while the
apparent dissociation constants (Km) increased suggesting quercetin inhibits catechol oxidation
competitively and is described as Equation 2.8 where KCA is the dissociation constant of Cu(II)Bc-catechol complex and Ki is the inhibition constant.
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Equation 2.8

(

𝑖 )

Equation 2.9
𝑐𝑎𝑡 𝑐
𝑐𝑎𝑡 𝑐
Lineweaver-Burke plot is a useful graphic method used often in enzyme kinetics
inhibition study. The inverse of substrate concentration (1/[S]) and the inverse of Vmax (1/ Vmax)
were plotted (Figure 2.17) and the data were fit to Equation 2.10.
Equation 2.10
(

)

The linear plot showed a converged point slightly before the y-intercept, indicating a
competitive inhibition. Using Equation 2.8, where

replaced by Km in Equation

2.9., the inhibition constant (Ki) of quercetin toward catechol oxidation by Cu(II)-Bc complex is
4.82 μM (Figure 2.16).
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Quercetin inhibition toward catechol oxidation by 2uM CuBc in 100mM HEPES
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Figure 2.16: Different concentration of quercetin to 1 μM Cu(II)-Bc with varying catechol
concentrations in 100 mM HEPES buffer at pH 7.0 at 25 ºC.

Table 2.7: Catalytic parameters of different concentration of quercetin to 1 μM Cu(II)-Bc with
varying catechol concentrations in 100 mM HEPES buffer at pH 7.0 at 25 ºC.
0.5 μM

0.8 μM

1.4 μM

2.2 μM

Quercetin

Quercetin

Quercetin

Quercetin

(Rs=0.9959)

(Rs=0.9934)

(Rs=0.9992)

(Rs=0.9989)

Vmax (mM/s)

(1.93 ±0.15)×10 ‒5

Km (mM)

3.19±0.51

kcat (s–1)

9.65×10

kcat/Km

3.02×10

–5

(1.74±0.15)×10
3.29±0.51

–3

–5

(1.80±0.08)×10
4.39±0.37

–3

8.72×10
–3

–3

(mM–1 s–1)

78

5.67±0.60

–3
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2.64×10

–5
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–3
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–3
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–3

1.73×10

Quercetin inhibition toward catechol oxidation by 2uM CuBc in 100mM HEPES
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Figure 2.17: Lineweaver-Burke plot of different concentration of quercetin to 1 μM Cu(II)-Bc
with varying catechol concentrations in 100 mM HEPES buffer at pH 7.0 at 25 ºC.

In Figure 2.15, with increasing amounts of hydrogen peroxide, catechol oxidation rate
generated by Cu (II)-Bc complex increases indicating hydrogen peroxide participating in catalytic
redox cycle. Quercetin inhibition of catechol oxidation by Cu(II)-Bc complex with the presence
of saturating amount of hydrogen peroxide were also investigated (Figure 2.18). The Hanes
analysis experiments were done with the presence of 10 mM hydrogen peroxide (Figure 2.19 and
Table 2.8). With increasing amounts of quercetin, the Vmax values decreased and the apparent
dissociation constants remained similar considering the standard deviations suggesting quercetin
uncompetitively inhibited the catechol oxidation by Cu(II)-Bc complex with the presence of
saturating amount of hydrogen peroxide. The data were reprocessed as Lineweaver-Burke plot in
Figure 2.19, it seems to be consistent with the uncompetitive inhibition pattern. The data in Figure
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2.18 were fit to Equation 2.11, and the inhibition constant (Ki) of catechol oxidation by Cu(II)-Bc
complex with the presence of saturating amount of hydrogen peroxide is 14.85 μM.

Equation 2.11

(

𝑖 )

Hanes of Quercetin inhibition toward 1uM Cu-Bc with 10mM peroxide

3e-5

3e-5
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Figure 2.18: Different concentration of quercetin to 1 μM Cu(II)-Bc and 10 mM H2O2 with
varying catechol concentrations in 100 mM HEPES buffer at pH 7.0 at 25 ºC.
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Table 2.8: Catalytic parameters of different concentration of quercetin to 1 μM Cu(II)-Bc and 10
mM H2O2 with varying catechol concentrations in 100 mM HEPES buffer at pH 7.0 at 25 ºC.

Vmax (mM/s)

1 μM Quercetin

4 μM Quercetin

8 μM Quercetin

16 μM Quercetin

(Rs=0.9944)

(Rs=0.9907)

(Rs=0.9888)

(Rs=0.9972)

–

(3.21±0.19)×10

–5

(2.83±0.22)×10

–5

–5

(1.96±0.16)×10

(1.82±0.07)×10

5

Km (mM)

0.62±0.10

0.72±0.15

0.56±0.14

0.55±0.06

kcat (s–1)

0.032

0.028

0.020

0.018

kcat/Km

0.051

0.039

0.035

0.033

(mM–1 s–1)
Quercetin inhibition toward 2mM catechol oxidation by 1uM Cu(II)-Bc with 10mM peroxide
in 100 mM HEPES at pH 7

0.012

1/ Rate (mM/s)

0.010
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8 uM quercetin
16 uM quercetin

0.008

0.006

0.004

0.002
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Figure 2.19: Lineweaver-Burke plot of different concentration of quercetin to 1 μM Cu(II)-Bc
and 10 mM H2O2 with varying amounts of catechol in 100 mM HEPES buffer at pH 7.0 at 25 ºC.
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To conclude, quercetin inhibits catechol oxidation by Cu(II)-Bc with and without the
presence of hydrogen peroxide, affording inhibition constants 4.82 μM and 14.85 μM
respectively. The UV-vis optical study demonstrated the binding of quercetin to Cu(II), Co(II),
Cu(II)-Bc and Co(II)-Bc complexes. By using Co(II) as a probe for paramagnetic metal and
ligand binding, the ternary complex of Co(II)-Bc-quercetin was demonstrated. Combined with the
catechin and epicatechin study, the project demonstrated different types of chemical interactions
between various phytochemicals with neighboring biomolecules through the metal center.

NMR data: Metal binding to quercetin46b and bacitracin9, 22, 25 have been previously demonstrated
through different physical methods. Quercetin has three potential metal binding site: βketophenolate, α-ketoenolate, and the catechol moiety, and using Co(II) as a probe, the
paramagnetic NMR results showed α-ketoenolate moiety was directly interacting with the metal
center through the method of saturation transfer. Co(II) was shown to coordinate with bacitracin
through the thiazoline ring Nε nitrogen of His-10, and the carboxylate side chain of D-Glu-4.25
Paramagnetic NMR is extremely sensitive to changes of coordination environment near the active
site due to the strong electron magnetic moment of the unpaired electron in a paramagnetic
system. Co(II) is usually used as a paramagnetic probe for Cu(II) and it does not cause
overwhelming line-broaden like Cu(II) allowing us to monitor changes upon paramagnetic metal
ligand binding. Upon metal binding to a ligand, it forms the ML complex which is constantly
under exchanged with the free form ligand (

). The chemical shifted signals of free

form ligand show up within the diamagnetic region (0-15 ppm), and upon a paramagnetic metal
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binding to the ligand, it causes isotropic shifted signals outside the diamagnetic region. The
relaxation rate of the proton is affected by the unpaired electron from the metal, and the closer the
proton is to the metal center, the more it is affected and leads to shorter the nucleus relaxation rate
of the proton and board chemical shifts. The 1H NMR spectrum (Figure 2.20) of 8 mM Co(II)-Bc
and Co(II)-Qr in d6-DMSO show several characteristic chemical shifts indicating bacitracin and
quercetin can both coordinate with Co(II) center and forming two different complexes. The results
from kinetic inhibition study suggested that quercetin interacted with the Cu(II)-Bc complex by
inhibiting the metal-mediated redox. To demonstrate the ternary complex formation of Cu(II)-BcQr, one equivalent of bacitracin was added to 8 mM of Co(II)-quercetin complex in d6-DMSO.
The 1H NMR spectrum of 8 mM Co(II)-Bc-Qr (Figure 2.20: middle spectrum) was collected and
compared to the spectra of Co(II)-Bc and Co(II)-Qr under same condition, and the ternary
complex showed clear differences. In Figure 2.20 (bottom spectrum) the characteristic peaks of
1:1 Co(II)-Qr at –80, 14 and 49 ppm disappeared in the ternary complex. At the bottom spectra of
Figure 2.20, the characteristic peaks of 1:1 Co(II)-Bc (top spectrum) at –28, –19, 26, 41 and 58
ppm also disappeared in the ternary complex. Moreover, the formation of new peaks was
observed at –56, –26, –17, 13 and 37 ppm in the ternary complex. From the compared 1H NMR
spectrum, the ternary complex formation of Co(II)-Bc-Qr was established.
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Figure 2.20: 1H NMR spectra of 8 mM Co(II)-Bc, middle: Co(II)-Bc-Qr, bottom: Co(II)-Qr in d6DMSO with two equivalents of TEA.

Oxidation Activity by Cu(II)-Bacitracin Analogue

Bacterial resistance toward antibiotics is an alarming issue that CDC proposed several
approaches to halt the antibiotic resistance, and among which, the chemical characterization of
structural analogues and their activities of biologically active lead compounds. Bio-active
peptides based antibiotics such as bacitracin (Figure 2.21) usually contain unique motifs such as
cyclic structures, unusual amino acids, D-amino acids, sugar moiety, and lipid tails. 58 Commonly
used drugs such as amphomycin, actinomycin, cephalosporin, gramicidin, polymyxin and
vancomycin are examples. Regardless of the widely uses of bacitracin in pharmaceutical and
livestock industries, bacterial resistance toward bacitracin remains low, and this is most likely due
to its unique mode of action.9 Bacitracin required metal ion to be bioactive, and in order to fully
understand the structure function relationship of metal and bacitracin, bacitracin analogue
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replacing the thiazoline moiety with a pyrrolidine moiety and replacing the tail with a histidinelike moiety (imidazole). Previous study showed that the carboxylate group on Glu-4 and the Ɛnitrogen on imidazole of His-10 are responsible for metal binding,22 by removal of the thiazoline
moiety, the change of coordination environment may influence the activity. In this study, the
catalytic activity of Cu(II)-bacitracin and Cu(II)-bacitracin (Cu(II)-HFBc) analogue will be
compared.

Figure 2.21: Chemical structure of bacitracin analogue (HFBc).

Cu(II)-Bc complex followed pre-equilibrium enzyme like kinetics performing catechol
and DTBC oxidation22 with and without the presence of hydrogen peroxide.22 10 μM Cu(II)HFBc was incubated with increasing amount of catechol/MBTH mixture in 100 mM HEPES
buffer solution at pH 7 at 25 ºC. The oxidized pink o-quinones showed up around 500 nm, and the
changes in absorption were measured as a function of time (Figure 2.22). The results showed
Cu(II)-HFBc also following pre-equilibrium enzyme like kinetics and can be described in
Equation 2.12. The catalytic parameters of both complexes were summarized in Table 2.9. The
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kcat value of Cu(II)-HFBc is 0.03 s–1, which is 7.5-fold higher than Cu(II)-Bc (0.004 s–1). The
apparent dissociation constant of Cu(II)-HFBc-catechol is 0.44 mM while Cu(II)-Bc-catechol is
3.88 mM, a 8.8-fold decrees in Km suggesting more stable intermediate complex of Cu(II)-HFBccatechol. The overall kcat/Km values of Cu(II)-HFBc and Cu(II)-Bc are 0.07 mM–1 s–1 and 0.001
mM–1 s–1; Cu(II)-HFBc is 70-fold faster in catalyzing catechol oxidation.
Equation 2.12

Catechol oxidation by 10 uM Cu(II)-HFBc and 2 uM Cu(II)-Bc in 100mM HEPES at pH 7

5e-5
10 uM Cu-HFBc
2 uM Cu-Bc

Rate (mM/s)

4e-5

3e-5

2e-5

1e-5

0
0

1

2

3

[catecho] mM

Figure 2.22: Catechol oxidation by Cu(II)-HFBc and Cu(II)-Bc in 100 mM HEPES buffer at pH
7.0 at 25 ºC.
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Table 2.9: Catalytic parameters of catechol oxidation by Cu(II)-HFBc and Cu(II)-Bc in 100 mM
HEPES buffer at pH 7.0 at 25 ºC.

Vmax (mM/s)

Cu(II)-HFBc

Cu(II)-Bc

(Rs=0.9950)

(Rs=0.9999)

–5

5.27 ×10

(9.09±0.20) ×10

Km (mM)

0.44 ±0.05

3.88±0.13

kcat (s–1)

0.052

0.0045

kcat/Km

0.07

0.001

–6

(mM–1 s–1)

A complex can show specificity among different substrates; another catecholate substrate,
3, 5, di-tert-butyl catechol (DTBC), was used to probe the catalytic activity between the two
complexes: Cu(II)-HFBc and Cu(II)-Bc. The o-quinones formation for DTBQ appeared a 410 nm
in 50/50 DMSO/100 mM HEPES buffer at pH 7.0 and the change in absorption was measured as
a function of time (Figure 2.23). DTBC oxidation by Cu(II)-HFBc and Cu(II)-Bc complexes
followed pre-equilibrium enzyme like kinetics and were fit to Equation 2.13, affording kcat of 0.02
and 0.004 s–1 and Km values of 5.08 and 6.14 mM respectively (Table 2.10). The kcat/Km of
Cu(II)-HFBc and Cu(II)-Bc complexes 0.003 and 0.006 mM–1 s–1 .
Equation 2.13
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DTBC oxidation by 5uM of Cu(II)-HFBc and 20 uM of Cu(II)-Bc in 50/50 DMSO 100mM HEPES buffer at pH 7

0.00012
5 uM Cu(II)-HFBc
20 uM Cu(II)-Bc
0.00010

Rate (mM/s)

0.00008

0.00006

0.00004

0.00002

0.00000
0

2

4

6

8

10

12

14

[DTBC] mM

Figure 2.23: DTBC oxidation by Cu(II)-HFBc and Cu(II)-Bc in 50/50 DMSO/100 mM HEPES
buffer at pH 7.0 at 25 ºC.
Table 2.10: Catalytic parameters of DTBC oxidation by Cu(II)-HFBc and Cu(II)-Bc in 50/50
DMSO/100 mM HEPES buffer at pH 7.0 at 25 ºC.

Vmax (mM/s)

Cu(II)-HFBc

Cu(II)-Bc

(Rs=0.9950)

(Rs=0.9999)

–4

–5

1.0 ×10

8.90×10

Km (mM)

5.08 ±1.62

6.14 ±1.67

kcat (s–1)

0.02

0.004

kcat/Km

0.003

0.0006

(mM–1 s–1)

Unlike dioxygen that only binds to reduced Cu(I) center, hydrogen peroxide binds directly
to Cu(II) center and go through redox. From previous catechol and DTBC oxidation studies,
Cu(II)-HFBc is more efficient at catalyzing the conversion of catecholate substrates into their o88

quinone products compared to Cu(II)-Bc. In Figure 2.24, the concentration of catalyst and
catechol were fixed, and increasing amounts of hydrogen peroxide concentration were added. The
results followed pre-equilibrium enzyme like kinetics and perform peroxidation efficiently. The
data were fit to Equation 2.14, and catalytic parameters were summarized in Table 2. 11. The kcat
of both Cu(II)-HFBc and Cu(II)-Bc are 0.02 s–1 while the Km of Cu(II)-HFBc-DTBC is 4-fold
higher than Cu(II)-Bc-DTBC suggesting less stable intermediate of Cu(II)-HFBc-DTBC. The
resulting kcat/Km of Cu(II)-HFBc and Cu(II)-Bc are 0.001 and 0.005 mM–1 s–1 respectively.
Equation 2.14

Peroxide saturation on 8 mM DTBC oxidation by 5 uM Cu-HFBc and Cu-Bc in 50/50 DMSO/100 mM HEPES pH 7

0.0010
5 uM Cu-HFBc
5 uM Cu-Bc

Rate(mM/s)

0.0008

0.0006

0.0004

0.0002

0.0000
0

50

100

150

200

250

300

[peroxide]mM

Figure 2.24: Peroxide saturation of 8 mM DTBC oxidation by 5 μM of Cu(II)-HFBc and Cu(II)Bc in 50/50 DMSO/100 mM HEPES buffer at pH 7.0 at 25 ºC.
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Table 2.11: Catalytic parameters of peroxide saturation of 8 mM DTBC oxidation by 5 μM of
Cu(II)-HFBc and Cu(II)-Bc in 50/50 DMSO/100 mM HEPES buffer at pH 7.0 at 25 ºC.

Vmax (mM/s)

Cu(II)-HFBc

Cu(II)-Bc

(Rs=0.9950)

(Rs=0.9999)

(1.0±0.07)×10

–3

(1±0.03)×10

Km (mM)

139 ±22

35 ±5

kcat (s–1)

0.2

0.2

kcat/Km

0.001

0.005

–3

(mM–1 s–1)

The Binding and Oxidation Activity of Fe(III)-Bacitracin Complex

Bacitracin is a metallo-antibiotic that requires divalent metals to be bioactive and can
coordinate to various transition metals such as Zn2+, Cu2+., Mn2+., Co2+., and Ni2+,9, 25, 59 however,
the binding and activity with iron remain unknown. Iron is the fourth most abundant element on
earth and almost all biological system incorporate it for various function. For example, transferrin
is responsible for iron transport in human body, while bacteria use siderophore for intake of ferric
iron. Iron dioxygenases are iron containing protein that bind and activate dioxygen, and are
divided into two types: extradiol and intradiol cleavage enzyme.60 Like Cu(II), Fe(III) can go
through redox efficiently producing reactive oxygen speices, and with accumulated amounts of
ROS, they potentially leads to cytotoxicity. Iron concentration in biological systems is strictly
regulated; disruptions in iron regulation will lead to serious consequences such as anemia and iron
overload.61
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The purpose of study is to investigate the structure activity relationship of Fe(III)bacitracin complex. Bacitracin is produced by the soil bacterial Bacillus subtilis, and is a metalloantibiotic shown to bind with Co(II), Mn(II), Cu(II), and Zn(II);62 however the interaction with
Fe(III) remain unclear. Bacitracin has several potential metal binding sites which can coordinate
with Fe(III) center and go through redox cycle. The typical iron concentration in soils ranges from
0.2% to 55% (20,000 to 550,000 mg/kg).63 Since bacitracin and iron are both present in soil, this
project provides an opportunity to explore the chemical micro-ecology in soil by investigating the
chemical interactions between Fe3+ and bacitracin.
Results and Discussion: the active site of bacitracin contains potential metal binding sites
including histidine, glutamic acid and aspartic acid, and iron(III) has strong affinity toward
oxygen and nitrogen containing moieties. Providing that iron(III) is considered as a strong Lewis
acid, given the suitable condition, it can coordinate with bacitracin through amino acid side
chains. The metal binding of iron(III) toward bacitracin was studied with UV-Vis, paramagnetic
NMR spectroscopy, and resonance Raman spectroscopy.
UV-Vis : to demonstrate bacitracin binding to iron (III), different equivalents of bacitracin were
titrated into 100 μM of iron (from FeCl3), in methanol and monitored from 200 nm to 600 nm
(Figure 2.25). The electron transition spectra of free Fe3+ showed an intense absorption around
375 nm. Upon titration of different equivalents of bacitracin, a new absorption gradually grew
around 315 nm, and the intensity of the absorption at 375 nm decreased. From Figure 2.25, the
appearance of the peak at 315 nm and the isosbestic point indicated the formation of Fe(III)-Bc
complex. To obtain the binding constant of Fe3+ to bacitracin, the molar absorptivity of each
addition at 320 nm were plotted against the concentration of bacitracin (Figure 2.26). The data
were fit to Equation 2.16 and the resulting affinity constant of bacitracin to iron(III) in methanol
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was 1.77 × 104 M–1. The equation provided Kd value which is inverse of Kf constant, and the Rs
value is 0.9898.
Iron-catecholate complexes generate intense ligand to metal charge transfer band usually
within the UV-vis range of 500 to 800 nm. The location of where the LMCT band appear
correlates to its catalytic activity; the more red shifted the LMCT band is, the less reactive it
becomes, while the more blue shifted the LMCT band is, the higher catalytic activity it
performs.64 To demonstrate substrates binding to Fe(III) and Fe(III)-Bc, one equivalent of each
substrate was added to Fe(III) and Fe(III)-Bc in methanol (Figure 2.27 and 2.28). The results from
each complex showed clear LMCT bands at different frequency. Among which, DTBC
complexes showed the most blue-shifted band (~1000 nm) indicating highest catalytic activity
while DCC and catechol LMCT band appeared around 750 to 800 nm suggesting less active
complexes.
Bacitracin titration to 100uM Fe in DMSO
0.5
100uM Fe
100uM Fe+ Bc eq 0.1
100uM Fe+ Bc eq 0.2
100uM Fe+ Bc eq 0.3
100uM Fe+ Bc eq 0.4
100uM Fe+ Bc eq 0.5
100uM Fe+ Bc eq 0.6
100uM Fe+ Bc eq 0.7
100uM Fe+ Bc eq 0.8
100uM Fe+ Bc eq 0.9
100uM Fe+ Bc eq 1.0
100uM Fe+ Bc eq 2.0
100uM Fe+ Bc eq 4.0

0.4

abs

0.3

0.2

0.1

0.0
300

400

500

600

nm

Figure 2.25: Bacitracin titration to 100 μM of FeCl3 in methanol at 25ºC.
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Bacitracin tiration to 0.1 mM Fe(III) in DMSO

4000

Molar absorptivity (M-1 cm-1)

3800
3600
3400
3200
3000
2800
2600
0.0000

0.0001

0.0002

0.0003

0.0004

0.0005

[Bacitracin] M

Figure 2.26: Bacitracin titration to 100 μM of FeCl3 in methanol at 315 nm at 25ºC.
Substrates binding to 0.125mM FeBc in methanol
0.20
1:1 FeBc: catecchol
1:1 FeBc: DCC
1:1 FeBc: DTBC

abs

0.15

0.10

0.05

0.00
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Figure 2.27: Catechol, DCC and DTBC titration to 0.125 mM Fe(III)-Bc in methanol at 25 ºC.
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2D Graph 3
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Figure 2.28: Catechol, DCC and DTBC titration to 0.125 mM Fe(III) in methanol at 25 ºC.

Querceitn has three potential metal binding site and previous study concluded that it binds
with Co(II)-beta amyloid complex through the α-ketoenolate moiety of quercetin from optical
UV-vis and paramagnetic NMR study.46b In previous sections, the interaction of various
phytochemicals including catechin, epicatechin, EGCG and quercetin with Cu(II)-Bc were
investigated. In this section, the binding of quercetin to Fe(III)-Bc were demonstrated.
To establish the interaction between iron(III)-Bc with quercetin, iron(III)-Bc complexes
were titrated to 5 μM of quercetin in methanol monitoring from 200 nm to 800 nm (Figure 2.29).
Apo-quercetin showed two characteristic intense absorptions around 300 nm and 380 nm. With
additions of different equivalents of iron(III)-Bc complex, the absorption at 380 nm started to
decrease. The absorption at 380 nm represents the catechol and α-ketoenolate moieties, and the
paramagnetic NMR results showed Co(II) binding to quercetin through the α-ketoenolate moiety.
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Besides the disappearance of the 380 nm absorption, a new absorption and an isosbestic point
appeared at 450 nm with additions of complex. On the contrary, in Figure 2.30, upon titration of
free Fe3+ to 5 μM quercetin in methanol, the characteristic absorption of quercetin at 380 nm
decreased slightly, and a less defined absorption emerged at 450 nm indicating the weak binding
formation of Fe3+-Qr complex. The binding affinity of Fe(III)-Bc complex to quercetin was
obtained through Figure 2.31, the data were fit to Equation 2.26 assuming 1:1 binding. The
resulted affinity constant of bacitracin-iron(III) to quercetin in methanol to be 3.43×105 M–1 with
Rs value of 0.9636.

Optical titration of Fe(III)-Bc complex to 5 uM Quercetin in MeOH

Molar absorptivity (M-1 cm-1)

50000
5 uM Quercetin
0.2 eq of Fe(III)-Bc
0.4 eq of Fe(III)-Bc
0.6 eq of Fe(III)-Bc
0.8 eq of Fe(III)-Bc
1 eq of Fe(III)-Bc
2 eq of Fe(III)-Bc
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20000
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0
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Figure 2.29: Fe(III)-Bc complex titration to 5 μM of quercetin in methanol at 25 ºC.
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Fe Titration into Quercetin
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Figure 2.30: Fe(III) titration to 5 μM of quercetin in methanol at 25 ºC.

Fe(III)-Bc titration to 5 uM Quercetin at 450 nm
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Figure 2.31: Fe(III)-Bc complex titration to 5 μM of quercetin in methanol at 450 nm at 25 ºC.
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NMR Spectroscopy Results: paramagnetic proton NMR is extremely sensitive to changes
near the active site and coordination environment. This is due to the strong electron magnetic
moment of the unpaired electron in a paramagnetic system. The electron magnetic moment of an
unpaired electron in paramagnetic system is 658-fold stronger than a proton in diamagnetic
system. This increases the sensitivity and allows electron-nuclear hyperfine interaction to be
observed in a paramagnetic system. Upon metal binding to a ligand, it follows the reaction
, and the ML complex is constantly under exchanged with the free ligand (L). When
ligand is metal-free, the chemical shifted signals show up within the diamagnetic region (0-15
ppm), upon a paramagnetic metal binding to the ligand, it causes isotropic shifted signals outside
the diamagnetic region. The relaxation rate of the proton is affected by the unpaired electron from
the metal, and the closer the proton is to the metal center, the more it is affected, resulting in
shorter nucleus relaxation rate of the proton. Due to the overwhelming electron magnetic moment
of Fe3+, at high spin configuration it contain five unpaired electrons, the resulted 1H NMR usually
have board signals.
The 1H NMR spectrum of Fe(III) to bacitracin was performed in non-deuterated methanol
(Figure 2.32), the results displayed two paramagnetic shifted signals near the spectral window of
20 to 45 ppm. Due to the high proton concentration in non-deuterated methanol, a water
suppression technique superWEFT was applied to the 1H NMR spectrum. Super-WEFT stands for
Water Eliminated Fourier Transform (pulse sequence: τ1-180°-τ2-90°-FID), which is very useful
for selectively suppressing slow diamagnetic signals. The resulted spectrum successfully
displayed two paramagnetic isotropic shifted signals which is direct evidence of Fe3+ binding to
bacitracin. This is consistent with previous optical UV-vis study.
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Figure 2.32: 8 mM of Fe(III)-Bc in methanol at 600 MHz field strength. Super-WEFT pulse
sequence (d1= 65.0 ms, d2= 25.0 ms, p1= 25 μs, pw= 8 μs, acquisition time= 25.0 ms at 320k Hz).

Resonance Raman Spectroscopy Results: Resonance Raman spectroscopy uses the
principle of regular Raman spectroscopy by introducing a laser beam which has energy close to
the molecule’s electronic transition. When the laser irradiates similar energy bands, Raman scatter
signals are enhanced due to the frequency resonance. The clear ligand metal charge transfer bands
from cateholate-iron(III) complexes provide a great opportunity to investigate the system with the
use of resonance Raman spectroscopy.60b, 65 Any change in vibrational modes due to metal ligand
binding will be enhanced by resonance Raman. By assigning the resonance Raman signals, it
allows us to determine which moiety (moieties) are involved during metal binding. Extensive
works were done on using the charge transfer band of Fe(III)-catecholate, and Que demonstrated
the use of resonance Raman spectroscopy on Fe(III) containing metalloenzyme, phenylalanine
hydroxylase (PAH), which is responsible for catalyzingthe hydroxylation of phenylalanine to
tyrosine. By introducing a laser similar with the molecules electronic transition, the resulting
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resonance Raman spectrum can show clear enhancement of signals correlating to the changes in
stretches and vibrational modes.66
From the UV-vis results (Figure 2.27 and 2.28), both Fe3+ and Fe3+-Bc form charge
transfer band with all three catecholate, since catechol Fe3+ and Fe3+-Bc generate the most intense
LMCT bands, catechol will be used as the substrate for resonance Raman study. The resulted
resonance Raman spectrum was obtained by introducing a laser beam with 526 nm which is near
the LMCT band observed in UV-vis. From the result, it showed enhancement of several signals
and new Raman shifted signals (Figure 2.33). Most of the peaks were assigned based on literature
and summarized in Table 2.12. Fe3+-Bc-catechol has a Raman shifted signal at 526 cm–1 that is
associated with catecholate vibration, and for Fe3+-catechol, the catecholate vibration appears at
530 cm–1. One very clear change is the skeletal mode of ortho-disubstituted benzene of Fe3+-Bc at
620 cm–1. The intensity of the Raman shifted signal of ortho-disubstituted benzene is much more
defined and intense comparing to the one of Fe3+-catechol located at 626 cm–1, indicating changes
in electron density distribution due to the presence of bacitracin. The signal of Fe(III)-Bc-catechol
at 1145 cm–1 represents the C-H bending mode on the benzene ring. For Fe-catechol, the C-H
bending mode is much less intense and appears at 1148 cm–1. In the resonance Raman spectra of
Fe3+-catechol, there are two Raman shifted signals showing up at 1270 cm–1 and 1309 cm–1
representing the C-O stretch on benzene and the skeletal mode of ortho-disubstituted benzenes
respectively, while the two signals shifted to 1252 cm–1 and 1302 cm–1 in Fe3+-Bc-catechol. The
signals associated with the C-C stretches of benzene rings appear at 1468 cm–1 and 1570 cm–1 for
Fe3+-Bc-catechol complex, and three signals representing C-C stretch modes appear at 1448, 1574
and 1530 cm–1 in Fe-catechol complex.
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Comparing resonance Raman spectrum of Fe3+-catechol and Fe3+-Bc-catechol complexes,
there are clear differences in Raman shifted signals and peaks intensity. Since the vibrational
modes of a ligand can be affected by incoming metal ion or ligand binding, exciting the LMCT
band with similar energy, it enhance most of the signals that are associated with structural and
vibrational changes due to chemical interaction. In this study, I have successful demonstrated
using resonance Raman spectroscopy to confirm complex formation of Fe3+-Bc and its interaction
with catechol.

Figure 2.33: Resonance Raman spectrum of Fe(III)-Bc and Fe(III) in methanol by exciting with a
526-nm laser.
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Table 2.12: Signals assignments of resonance Raman spectrum of Fe(III)-Bc and Fe(III) in
methanol by exciting with 526 nm laser.
Fe3+-bacitracin-catechol

Fe3+-catechol

Raman Peak (cm–1)

Raman Peak (cm–1)

Catecholate vibration

526

530

Skeletal modes of ortho-

620

626

808

No peak

C-H bend

1145

1152

C-O stretch

1252

1270

Skeletal modes of ortho-

1302

1309

C-C stretch

1468

1448

C-C stretch

1570

1574

Peak assignments

disubstituted benzenes

disubstituted benzenes

Kinetics results: Fe(III)-catecholate generates an intense broad ligand to metal charge
transfer band (LMCT) in the range of 500 to 900 nm; the λmax of where the LMCT appears carries
important information about its catalytic activity. Fe(III)-catecholate that generates lower energy
LMCT (red-shifted) usually correlating to higher catalytic activity, and complexes that generate
higher energy LMCT (blue-shifted) correlate to lower catalytic activity.67 From Figure 2.27 and
2.28, DTBC showed the most red-shifted LMCT suggesting higher catalytic activity while
catechol showed more blue-shifted LMCT suggesting lower catalytic activity. In this study, the
kinetics measurements of catechol and DTBC oxidation by Fe3+-Bc and Fe3+ were investigated.
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In all the kinetic study, free Fe3+ (FeCl3) were used as controls to compare with Fe3+-Bc
complex activity. To check the catalytic activity of Fe3+-Bc, 3,5-di-tert butyl catechol (DTBC)
and catechol were used as the substrate to monitor oxidized product DTBQ toward DTBC
oxidation by Fe3+-Bc. Increasing amounts of substrate were incubated with 200 μM of Fe3+-Bc
and free Fe3+ control in 90% methanol and 10 % 200 mM HEPES buffer solution at pH 7 at 25
ºC, and the changes of absorption o-quinones were measured as a function of time for DTBC
(Figure 2.34) and catechol (2.35). The results suggesting Fe3+-Bc complex and Fe3+ followed preequilibrium enzyme like kinetics and was describe as Equation 2.16 and fit to Equation 2.17. The
resulting catalytic parameters of DTBC and catechol were summarized in Table 2.13 and Table
2.14 respectively. The frequency of where the LMCT band appears correlated to the catalytic
activity and previous UV otpical studied showed DTBC generate more blue shifted LMCT than
catechol. The kcat of DTBC is 0.0015 s–1 which is 3-fold higher than the kcat of catechol, 0.0005 s–
1

. The kcat/Km of DTBC and catechol are 1.0×10–3 and 6.39×10–4 respectively. The apparent

dissociation constants (Km) of Fe(III)-Bc-catechol and Fe(III)-Bc-DTBC are 0.78 and 0.84 mM,
which are 13 to 14-fold smaller than Fe(III) controls indicating the presence of bacitracin
enhances the catalytic activity of Fe(III) center. In both sets of kinetics data, Fe(III)-Bc complex
exhibited different catalytic activity compared both Fe(III), which further confirm the complex
formation of Fe(III)-Bc.
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Figure 2.34: DTBC oxidation by 200 μM Fe and Fe3+-Bc in 90/10 MeOH/200 mM HEPES pH
7.0 at 25 ºC.:

Table 2.13: Catalytic parameters of 200 μM Fe and Fe3+-Bc in 90/10 MeOH/200 mM HEPES pH
7.0 at 25 ºC.

Vmax (mM/s)

Fe only

FeBc

(Rs= 0.9980)

(Rs= 0.9818)

(8.0 ± 0.98)×10

–4

(3.0 ± 0.23)×10

Km (mM)

11.30 ± 2.18

0.84 ± 0.20

kcat (s–1)

0.004

0.0015

kcat/Km

3.0×10

–4

(mM–1 s–1)

103

1.0×10

–3

–4

Hydrogen peroxide can participate in catalytic redox reaction and usually enhance the
oxidation rates. To check whether hydrogen peroxide can interact with the Fe(III)-Bc complex,
different amounts of hydrogen peroxide were incubated with fixed amount of Fe(III)-Bc and
substrates, and the changes in absorption of DTBQ formation were measured as a function of time
(Figure 2.35 and 2.36). With increasing of hydrogen peroxide, both catechol and DTBC oxidation
by Fe(III)-Bc showed peroxide saturation and the catalytic parameters were summarized in Table
2.14 and 2.15). Catechol oxidation by Fe(III)-Bc required more hydrogen peroxide to reach
saturation compared to DTBC as substrate, the kcat of peroxide saturation of DTBC oxidation is
0.02 s–1 and catechol oxidation is 0.006–1. In Figure 2.39 and 2.40, saturating amount of hydrogen
peroxide were added to check DTBC and catechol oxidation by Fe(III)-Bc. In Figure 2.39,
increasing amounts of DTBC were incubated with 200 μM Fe and Fe3+-Bc with 100 mM H2O2 in
90% MeOH 10% HEPES pH 7.0 at 25 ºC and DTBQ absorption was measured as a function of
time, and the catalytic parameters were summarized in Table 2.16. The results showed hydrogen
peroxide increase the catalytic activity both Fe(III) and Fe(III)-Bc, especially for Fe(III)-Bc, the
kcat before hydrogen peroxide addition and after were 0.0015 s–1 and 0.062 s–1 respectively and
the kcat/Km were 0.001 mM–1 s–1 and 0.114 mM–1 s–1. In Figure 2.40, increasing amounts of
catechol were incubated with 10 μM Fe and Fe3+-Bc with 100 mM H2O2 in 90% MeOH 10%
HEPES pH 7.0 at 25 ºC and o-quinone absorption was measured as a function of time, and the
catalytic parameters were summarized in Table 2.17. The kcat of catechol oxidation by Fe(III)-Bc
is 0.0017 s–1 kcat/Km is 0.0098 mM–1 s–1. The catalytic results of DTBC and catechol oxidation
are consistent with the optical study of LMCT band, demonstrating the more blue-shifted the
LMCT band is, the higher the catalytic activity. In this study, Fe(III)-Bc-DTBC generated LMCT
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band near 900 nm and showed higher catalytic than catechol oxidation by Fe(III)-Bc whose
LMCT band located around 750 to 800 nm.
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Figure 2.35: Peroxide saturation of 20 μM Fe3+-Bc with 4 mM DTBC in 90% MeOH 10% 200
mM HEPES pH 7.0 at 25 ºC.

Table 2.14: Catalytic parameters of peroxide saturation of 20 μM Fe3+-Bc with 4 mM DTBC in
90% MeOH 10% 200 mM HEPES pH 7.0 at 25 ºC.
Rs=0.9879
Vmax (mM/s)

(4.0±0.39)×10–4

Km (mM)

36.62±12.64

kcat (s–1)

0.02

kcat/Km

5.4×10–4

(mM–1 s–1)

105

0.00030

0.00025

Rate (mM/s)

0.00020

0.00015
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0.00005

0.00000
0
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Figure 2.36: Peroxide saturation of 50 μM Fe3+-Bc with 4 mM catechol in 90% MeOH 10% 200
mM HEPES pH 7.0 at 25 ºC.

Table 2.15: Catalytic parameters of peroxide saturation of 50 μM Fe3+-Bc with 4 mM catechol in
90% MeOH 10% 200 mM HEPES pH 7.0 at 25 ºC.
Rs= 0.9951
–4

Vmax (mM/s)

3.0±0.2×10

Km (mM)

233.1±52.1

kcat (s–1)

0.006

kcat/Km

2.5×10

–5

(mM–1 s–1)

106

Fe
FeBac

0.014
0.012

rate (mM/s)

0.010
0.008
0.006
0.004
0.002
0.000
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[DTBC]mM

Figure 2.37: DTBC oxidation by 200 μM Fe and Fe3+-Bc with 100 mM H2O2 in 90% MeOH
10% HEPES pH 7.0 at 25 ºC.

Table 2.16: Catalytic parameters of DTBC oxidation by 200 μM Fe and Fe3+-Bc with 100 mM
H2O2 in 90% MeOH 10% HEPES pH 7.0 at 25 ºC.
Fe only
Vmax (mM/s)

(2.4±0.1)×10

FeBc
–3

(1.23±0.06)×10

Km (mM)

0.71±0.17

0.53±0.09

kcat (s–1)

0.012

0.062

kcat/Km

0.016

0.114

(mM–1 s–1)
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–2
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Figure 2.38: Catechol oxidation by 10 μM Fe and Fe3+-Bc with 300 mM hydrogen peroxide in
90/10 MeOH/200 mM HEPES pH 7.0 at 25 ºC.

Table 2.17: Catalytic parameters of catechol oxidation by 10 μM Fe and Fe3+-Bc with 300 mM
hydrogen peroxide in 90/10 MeOH/200 mM HEPES pH 7.0 at 25 ºC.

Vmax (mM/s)

Fe

FeBc

(Rs= 0.9982)

(Rs= 0.9857)

(3.39±0.09)×10

–5

(1.73±0.08)×10

Km (mM)

0.45±0.04

0.18±0.03

kcat (s–1)

0.0033

0.0017

kcat/Km

0.0075

0.0098

(mM–1 s–1)

108

–5

Concluding remarks: in this project, the interaction between ferric iron and bacitracin were
investigated through the use of various physical methods including UV-vis optical, paramagnetic
NMR spectroscopy and resonance Raman spectroscopy. Upon iron binding to catecholates, an
intense LMCT band was generated, and the frequency of where the LMCT band appears
correlated to its catalytic activity. From the UV optical results, DTBC generate more blue-shifted
LMCT compared to catechol, and their catalytic activity were compared, the kinetic results were
consistent with the UV optical results, confirming Fe(III)-Bc had higher catalytic ability in
performing oxidation than catechol with and without the presence of hydrogen peroxide.
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Chapter 3 Inhibition Study toward Cu(II)-Amyloid Oxidation
Introduction
Neurodegenerative diseases describe the progressive decrease or even loss of normal
functions of neurons and their structures in human brain.1 Neurodegenerative diseases are not
only progressive and irreversible, but there is no currently known cure for them. Such diseases
include Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS), Parkinson’s,
Huntington’s and Alzheimer’s disease. Among them, Alzheimer’s disease (AD) is one of the most
common and fatal neurodegenerative diseases in current-day society.2 According to the Center of
Disease Control and Prevention (CDC), an estimated 5.4 million Americans are affected by it.
Statistics have shown that it is the fifth leading cause of death for people who are 65 years old or
older and the sixth leading cause of death among all adults.3 Alzheimer’s disease typically results
in memory loss, unusual behavior, personality change and decreases in logical thinking in
patients, often requiring a great amount of daily and medical assistances.4 The total medical
healthcare cost for Alzheimer’s disease, including long-term health is estimated to be $236 billion
in 2016 from CDC. Alzheimer’s disease could be present in early stage of adult life and 90% of
the AD patients do not show characteristic symptoms until after the age of 60. Moreover, the
development rate of AD doubles every 5 years after age of 65. Currently, 15% of the United State
population is 65 years old or older, with a number projected to upsurge to 22% by 2050.3, 5 With
the growing number of AD patients, and no current known cure for them, Alzheimer’s disease
poses a serious threat to society; it is expected that the number and cost of AD patients will
increase significantly. Therefore, it is extremely crucial for scientists to investigate and elucidate
the pathology and chemistry of Alzheimer’s disease to further prevent, treat and even cure AD
and other neurodegenerative diseases.
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Alzheimer’s disease is the most common form of dementia, where around 60 to 80 percent
of dementia cases are associated with AD.6 In Alzheimer’s disease, there are usually several brain
structural changes such as the diffuse loss of neurons, buildup of Tau protein tangles and the
aggregation of insoluble amyloid plaques. These can be observed through different neuroimaging
techniques including magnetic resonance imaging (MRI), computed tomography (CT) and
especially positron emission tomography (PET) scan for detecting brain activity.3
The term “amyloids” was first introduced during the late 19th century and was generally
defined as extracellular filaments tissue deposits, also described as fibrils.7 In 1906, a ground
breaking discovery was presented by a Bavarian psychiatrist, Alois Alzheimer; who identified the
presence of amyloid plaques in AD patients. Amyloid plaques were later determined to be
comprised of peptide, which is derived from a amyloid precursor protein, APP.8 APP is singletransmembrane receptor-like protein and is presented ubiquitously in neural and non-neural cells.
Beta-amyloid (Aβ) peptide is a proteolytic product generated by APP upon sequential cleavage by
β- and γ- secretases. The cleaved peptide consists of 40–42 amino acids (DAEFR HDSGY
EVHHQ KLVFF AEDVG SNKGA IIGLM VGGVV IA) and can produce Aβ1 −16 and Aβ1−20
fragments by α-secretase and/or insulin degrading enzymes.9 Beta-amyloid is amphipathic in
nature; the N-terminus region contains hydrophilic residues while the C-terminus region contains
hydrophobic residues. The conformation of the peptide can be affected by several factors
including temperature, pH, and surrounding solvent systems. Beta-amyloids tend to be stable and
remain α-helix monomer or random coiled conformations at acidic and basic conditions (pH < 4
or pH > 7). The peptides become unstable under physiological conditions and tend to form βsheets and oligomers, allowing further aggregation. The aggregated beta-amyloid plaques are
suggested to induce oxidative stress and neurotoxicity.4, 10
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Beta Amyloid and Metals

Metals have been hypothesized to be involved with the pathogenesis of Alzheimer’s
disease since late 1990s.2 The concentration of metals in human body is strictly regulated where
even a small amount of free metals can be toxic and leads to various health issues. Reactive
oxygen species (ROS), such as peroxide and superoxide can be generated through metal redox
pathways Transition metals, such as copper and iron, can easily go through the redox cycle and
generate significant amounts of ROS to cause oxidative stress. High levels of metal ions including
Cu2+, Fe3+/2+ and Zn2+ have been observed in aggregated amyloid plaques with the concentration
of 0.39 mM, 0.94 mM and 1.055 mM respectively.11 In the in-vitro studies, all three metals
accelerated the aggregation of beta-amyloid plaques; however, by adding metal chelators, such as
ethylenediaminetetraacetic acid (EDTA), the aggregation process can be reversed.12 Various
experimental and physical spectroscopy techniques such as NMR, proton-induced X-ray
emission, immersion autometallography, synchrotron X-ray fluorescence, laser capture
microdissection coupled with X-ray fluorescence microscopy and epifluoresence microscopy
were used to confirm the presence and concentrations of metal ions in beta-amyloid plaques.12a, 13
Because metals promote the aggregation of beta-amyloid, scientists have been focusing on
elucidating the structure and activity relationship between beta-amyloid and metals.
Although correlation of beta-amyloid and metals have been extensively studied, the
coordination environment still remains unclear. Beta-amyloid peptide contains several potential
metal binding sites that are likely to coordinate with copper, zinc and iron ions. The three
histidine residues: His-6, His-13 and His-14 (DAEFR HDSGY EVHHQ KLVFF AEDVG
SNKGA IIGLM VGGVV IA) were demonstrated to be involved in metal binding.14 Lipid
peroxidation, DNA and protein oxidation can occur when accumulated amounts of free Fe2+/3+
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and Cu2+ are present in biological systems.15 Due to the redox-active nature of copper and iron
ions, their reduced forms interact with O2 and generate significant amounts of ROS through
various pathways, eventually resulting in induced oxidative stress in the Alzheimer’s disease
patients’ brains.2, 11b, 12a, 16 Copper(II)-Aβ has been widely studied due to its high concentration in
AD senile brains as well as its ability to perform redox chemistry and effectively generate ROS.
In a well regulated biological system, there are typical protective mechanisms against oxidative
stress and cytotoxicity. However, undesired chemistry and products (such as ROS) can be
generated when ill-regulated. 17
Cu2+-beta-amyloid complex can perform metal center mediated oxidation chemistry and
mimic catechol oxidase, a type-3 copper containing enzyme. During the each redox cycle, Cu2+Aβ16/20 can perform two electron transfers by oxidizing polyphenol-like catechol containing
substrates. Such substrates include catechol, 3,5-di-tert-butyl catechol (DTBC), and some
neurotransmitters

dopamine, epinephrine and norepinephrine.14c,

14d

The proposed oxidation

mechanism of catechol-containing substrates by dinuclear copper(II) center complex indicates
two potential pathways (Figure 3.1). The first pathway (Figure 3.1: steps F to H, followed by
steps B to D) describes the activity in the air, where the substrate binds to the dinuclear copper
center bridged by a hydroxyl group, get oxidized, then released as oxidized ortho-quinone product
(step G). The di-copper center is reduced to Cu(I), and upon dioxygen binding and electron
transfer from Cu(I) to O2 (step H), a dinuclear copper(II)-peroxo ternary complex is formed (step
B). This ternary intermediate can be one of three possible isoelectronic rearrangements: (μ-oxo)2Cu3+, μ–η1 :η1-1,2-peroxo-

and μ–η2 :η2-peroxo-

.18 Substrate is able to bind the

bridging peroxo-di-copper center and go through redox cycles (step C), giving out a second
oxidized ortho-quinone product and one water molecule(step D). With the presence of peroxide, it
119

can directly coordinate to two copper centers (step A), forming the bridging peroxo di-copper
intermediate (step B) then allowing substrate to bind and oxidized it (step C), releasing orthoquinone product and one water molecule (step D).14c, 18a

Figure 3.1: Proposed mechanism for oxidation by Cu(II) Peptide Complexes
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In past decades, the research focus of Alzheimer’s disease has expanded and while also
shifting focus on understanding the role of metal ions in AD. As discussed previously, redoxactive metal ions are involved in the development of amyloid plagues; significant amounts of
ROS can be generated through the redox cycles of metallo-amyloid complexes, which are formed
by self-assembling soluble amyloid fragments and metal ions.19 Cu2+-Aβ16/20 complex exhibits
pre- equilibrium enzyme-like kinetics and can catalyze the conversion from catechol and its
derivatives to oxidized o-quinone products.14c, 20 The aim of this study is to use synthetic and
natural compounds to inhibit the catechol oxidation mediated by the Cu2+-Aβ16/20 complexes. By
understanding the detailed chemistry of the various inhibitors, this study may shed some light on
inhibiting the oxidative stress associated with AD, while further acting as a model to drug
treatment design.
Triketones

Chemical compounds that contain a triketone moiety in their structure can display various
types of biological activity. Some triketone compounds are produced in nature by myrtaceous
plants and lichens.21 Triketone containing compounds play an important role in the agriculture
industry as allopathic agents to prevent the growth of surrounding plants and microbes. In 1982,
during the investigation of a triketone herbicide, 2-benzoyl-1,3-cyclohexanedione, an Fe(II)
containing enzyme 4HPPD, p-hydroxyphenylpyruvate dioxygenase, was discovered.22 4-HPPD is
an enzyme responsible for catabolism of amino acid tyrosine in many aerobic organisms,
catalyzing the conversion of 4-hydroyphenylpyruvate (HPP) to homogentisate. X-ray
crystallographic structure of Fe(III) binding to the plant and mammalian forms of 4hydroxyphenylpyruvate dioxygenases has been resolved(Figure 3.2).
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Figure 3.2: Crystal structure of plant and mammalian 4-hydroxyphenylpyruvate dioxygenases
(expressed by Escherichia coli BL21) (PDB ID: 1SQD). The Fe(III) atom is displayed in gray.23
From the discovery of 4-HPPD, researchers also found that triketone compounds can be
used for medical treatment towards Type 1 tyrosinemia. Tyrosinemia is a kind of congenial
disorder of tyrosine metabolism, generally described as irregulation of the metabolic breakdown
of the amino acid tyrosine. There are three types of tyrosinemia, where each type is caused by the
deficiency of certain enzymes and exhibits certain characteristic symptoms. Type 1 tyrosinemia is
the most serious form among the three types; it lacks the specific enzyme fumarylacetoacetate
hydrolase, which is vital for catalyzing the conversion of fumarylacetoacetate to acetoacetate and
fumarate. Type 1 tryosinemia affects about 1 in 100,000 of the general population and is
especially common in certain regions in Quebec, Canada, affecting about 1 in 1846 in the local
population.24 Accumulation of tyrosine in the patients will eventually causes progressive and
irreversible kidney and liver failure, requiring transplant. Nitisinone (NTBC) (Figure 3.3), a
triketone compound, is currently used as the main treatment for patients with type 1 tyrosinemia.
The mode of action for NTBC is by directly interacting with the Fe(II) metal center of p122

hydroxyphenylpyruvate dioxygenase, the enzyme which controls the second step in the
catabolism of tyrosine. By coordinating to the non-heme ferrous center, NTBC inhibits the toxic
accumulation of the intermediate fumarylacetoacetate accumulation in the body. 25

Figure 3.3: The chemical structure of Nitisinone (NTBC).
The crystal structures of 4HPPD and the triketone herbicide NTBC have been shown to
have an overall distorted octahedral geometry of Fe(II) in its active site coordinated through the βketoenolate moiety, with one glutamic acid and two histidine residues, along with three water
molecule; NTBC binding to the 4HPPD mode is shown (Figure 3.4).23,

26

The metal binding

ability and inhibition activity of NTBC toward oxidation by 4-HPPD provides the opportunity to
investigate the use of triketone-based compounds as potential treatments of metal-mediated
oxidations in neurodegenerative diseases, including Alzheimer’s disease.
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Figure 3.4: Model of predicting the binding mode of NTBC to 4-HPPD. Fe(II) atom is displayed
as purple.
Curcumins

Curuminoid is one of the most well-known linear diarylheptanoids and is the second class
of plant metabolites. There are two kinds of diarylheptanoids including cyclic (such as
myricanone) and linear (such as curcuminoid) diarylheptanoids (Figure 3.5).

In general,

diarylheptanoids have general framework with a 1,7-diphenylheptane skeleton backbone; the
framework contains two aromatic rings on opposite side, linked by a seven-carbon chain with
various substituted functional groups. Diarylheptanoid was first isolated in 1815; since then,
around 400 structurally similar compounds have been discovered.27 Diarylheptanoids are
naturally occurring compounds that have recently gained popularity due to their potential
therapeutic abilities; among these compounds, curcumin is one of the most studied.28
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Figure 3.5: Examples of cyclic and linear diarylheptanoid.
Curcuminoid describes a group of chemical and structural similar analogues including
curcumin, demethoxycurcumin and bisdemethoxycurcumin. Due to the low solubility of
curcumins, demethoxycurcumin and bisdemethoycurcumin were grouped along with it to increase
the solubility for supplements and drug formulations.29 Curcumin is a plant-derived polyphenolic
compound found in the rhizome of the herb Curcuma longa, the root also known as turmeric.
Curcumin has a characteristic bright yellow color which contributes to the yellowness in the
cooking spice, curry. Besides the popular use of curcumin as kitchen spice, it has been used since
4,000 years ago in Chinese and Ayurveda medicine and health supplements. Curcumin was used
as an anti-inflammatory agent over past centuries, and with extensive study over the past few
decades, it is now considered as a board-spectrum compound which displays various biological
and pharmacological activities. Studies have shown curcumin to be an antioxidant30, antiinflammatory30b,

31

, angiogenesis (inhibition of blood vessel growth)32 and antiproliferative

(suppress cell growth) agent.33 Since curcumin can act as free radical scavenger and antioxidant,
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its potential treatment toward inhibiting the oxidative stress generated in neurodegenerative
diseases attracts a lot of attentions, particulaty in the case of Alzheimer’s disease.34
Curcumin contains a β-di-ketone-enolate moiety in the center that undergoes keto–enol
tautomerism, where it can exist in the keto or enol form (Figure 3.6). Upon deprotonation of the
enol form, this site acts as an ideal metal binding site. Usually curcumin tends to exist in keto
form in both low and neutral pH while existence in enol form is mostly in basic conditions.

Figure 3.6:Top: basic representation of keto-enol tautomerism. Bottom: curcumin under ketoenol tautomerism.
Curcumin has been demonstrated to coordinate with various metals including transition
metals and alkaline earth metals.34d Metal-curcumin complexes have been prepared and show
different analytical and medial application; for example, in 2004, a vanadyl compound VO(cur)2
was reported to exhibit significant antirheumatic activity in synoviocytes, as well as inhibiting
angiogenesis in both smooth muscle cells and mouse lymphoma cells.35 Ga68-curcumin and its
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derivative complexes were prepared and showed high affinity towards the A549 lung cancer cell,
and additionally can potentially be applied to cancer-detecting radiotracer in imaging. The Ga68(curcmin)2 complex also showed high affinity towards insoluble Aβ40 fibril after incubation.
Again, this can be an imaging tool when it comes to evaluating cytotoxic insoluble Aβ40 fibrils in
Alzheimer’s disease.36

Material and Methods
Curcumonins, disdemethoxycurcumin, demethoxycurcurmin, dopamine, pyrocatechol,
~99% (CA), dimethyl sulfoxide DMSO (99.9%), 3-methyl-benzyl-thiazolinone hydrochloride
(MBTH), CuSO4 salts (99.99%) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonate buffer
(HEPES) were purchased from Sigma-Aldrich Chemical Co. All chemicals listed above were
used without further purification, while the deionized water (18.2 MΩ) was obtained from a
Millipore Milli-Q system. The purity of all solvents and reagents were the highest grade of
commercial available sources. Beta-amyloid1-16(20) was synthesized by the Peptide Synthesis and
Mass Spectrometry Center at the University of South Florida. An Agilent MALDI-TOF mass
spectrometer and Dionex Summit HPLC system were used to confirm the purity of peptide.
Cu(II)-Aβ complex solution was prepared through literature procedure.37 Cu(II)-Aβ complex
solution was prepared shortly before each experiment in order to prevent peptide aggregation,
which could affect concentration differences. Triketone compounds were synthesized by Dr.
Yang’s group at Tunghai University in Taiwan. The triketone sample stock solutions were
prepared by dissolving triketone either in DMSO or methanol.23
In both triketone and curcuminoid studies, all the complex, substrate, and inhibitor
solutions were freshly prepared just prior to the experiments. A quartz cuvette was used in UV
optical and kinetics experiments.
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Optical Study

All samples for UV-Vis optical studies were in 100 mM HEPES buffer solution at pH 7.0 and 25
ºC. A Cary 50 spectrometer was used to collect all electronic spectra. NMR samples were all
prepared in d6-DMSO. CoCl3 was dissolved in d6-DMSO as the Co(II) source. Two equivalents of
triethylamine (TEA) were added to ensure fully deprotonated metal binding sites. 1D and 2D 1H
NMR spectra were collected on a Varian INOVA600 spectrometer (600 MH) with a 5-mm biotriple resonance probe. A 90° pulse of 7 μs was applied for the acquisition of 1D 1H NMR spectra.
To process the spectrum, line boarding of 50 Hz was applied.
Kinetics Study

Inhibition studies were done by titrating different amounts of inhibitors into catechol
oxidation by Cu2+-Aβ in 100 mM HEPES buffer solution at pH 7 and 7.5. O-quinone/MBTH
products were monitored at 500 nm with corresponding molar absorptive of 32500 cm–1M–1. For
detailed kinetics methods, see to chapter two material and methods section.

Results and Discussion
Triketone

β-ketoenolate moiety of the triketone compound was shown to be involved in metal
binding in the study of the treatment of type 1 tyrosinemia by the drug Nitisinone (NTBC).
Besides having ideal metal binding sites, NTBC also inhibits the metal mediated oxidation by
Fe(II) in the active site of 4-hydroxyphenylpyruvate dioxygenase (4-HPPD). These two features
prompted my search into whether triketone compounds can potentially interact with the copper(II)
center in metallo-beta-amyloid complex, in addition to further inhibiting the metal mediated
oxidation chemistry of from Cu-Aβ20. Initial screening on a few dozen synthetic triketone
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compounds revealed several active compounds that show inhibitory activity towards the metal
mediated oxidation chemistry of Cu-Aβ20 (Figure 3.7).

Figure 3.7: Various triketone compound inhibitory activity toward Cu(II)-Aβ20 in 100 mM
#21, (□) #10, (●) #39).

UV-vis Results: the binding of triketone compounds to Cu(II) center was investigated through
UV-vis. Two most active compounds (#16 and #21) and one inactive compound (#22) were
chosen as candidates for UV optical metal binding study (Figure 3.8). The near-UV electronic
transitions of the active triketone (#16 and #21) both show intense absorption at 395 and 390 nm
respectively, and the inactive apo-triketone (#22) absorbs at 375 nm in 100 mM HEPES buffer at
pH 7 and 25 ºC. After the addition of 1 equivalent of Cu2+ to each compound, a new absorption
peak appears at 407 nm, 415 nm and 425 nm respectively for #16-Cu(II), #21-Cu(II) and #22Cu(II). This is clear indication that all three triketone compounds, including active and inactive
ones, can all coordinate with Cu(II) (Figure 3.9).
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Figure 3.8: Chemical structures of active and inactive triketone compounds.
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Cu(II) binding to 10 uM triketone compounds in 100 mM HEPES at pH 7
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Figure 3.9: 10 μM Cu(II) titration to three different triketone #16 (active), #21 (active) and #22
(inactive) compounds in 100 mM HEPES at pH 7.0 and 25 ºC.

NMR Spectroscopy Results: NMR spectroscopy is a useful tool for molecular structure
elucidation, and for studying metal binding. Cu(II) is usually not a friendly metal to work with for
the paramagnetic metal binding study, in which the resulting spectrum show excessively broad
signals that are difficult to resolve. Due to the slow electronic relaxation rate of Cu(II) ranging 10–
8

to 10–11 s, which influences and decreases the nuclear relaxation times, resulting in broad NMR

signals. Instead, Co(II) has a much faster electronic relaxation rate which ranges from 10–11 to 10–
13

s; thus it can resolve relatively sharp paramagnetic shifted NMR signals.38
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Three triketone compounds were chosen for paramagnetic NMR study including the active
compound #21 and inactive compound #34 and #13. All samples were dissolved in d6-DMSO
with 2 equivalents of triethylamine (TEA) to ensure all metal binding sites of triketone
compounds were fully deprotonated. In order to suppress overwhelming proton signals from the
solvent, a water suppression technique (SuperWEFT) with the pulse sequence of τ1-180°-τ2-90°FID was applied. Applying SuperWEFT will affect the intensity of slow relaxation diamagnetic
signals, which resulted in distortion of the diamagnetic signals.39 Upon addition of one equivalent
of Co(II) to the triketone #21, the resulting 1H NMR spectrum showed three sharp shifted signals
at 22 ppm, 38 ppm and 81 ppm within the spectral window of 20 to 100 ppm (Figure 3.10). These
three paramagneticly shifted signals are due to the CH2 and CH protons at the β position of the
keto-enol metal-binding site. The signals assignment was further confirmed by comparing to the
1

H NMR spectrum of triketone #13, which does not contain the CH β-proton (Figure 3.11). The

1

H NMR spectrum of triketone #13 showed two paramagneticly shifted signals at 18 and 26 ppm

representing the two δ-protons. The metal binding site can be confirmed at the β-keto-enolate site.
In the case of the inactive triketone #34, upon Co(II) addition, the resulting paramagnetic
spectrum showed at least six shifted signals at 22 ppm, 26 ppm, 28 ppm, 38 ppm, 74 ppm and 76
ppm (Figure 3.12).
The NMR results which use Co(II) as a probe are consistent with the UV-vis optical
Cu(II) titrations, showing that both the active and inactive triketone compounds can coordinate
with metal centers. However, it is clear that the active sample #21 has more intense signals
compared to #34, the inactive sample. This could indicate that Co(II) has higher affinity toward
triketone #21, and can form a more stable complex than the inactive sample #34, where the
shifted signals are less intense with a poor signal-to-noise ratio, indicating weaker binding.
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Figure 3.10: 1H NMR at 600 MHz of 8 mM Co(II)-triketone #21 (active compound) in d6-DMSO
at 25 ºC.
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Figure 3.11: 1H NMR at 600 MHz of 8 mM Co(II)-triketone #13 (inactive compound) in d6DMSO at 25 ºC.

Figure 3.12: 1H NMR at 600 MHz of 8 mM Co(II)-triketone #34 (inactive compound) in d6DMSO at 25 ºC.
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Kinetics results: NMR and UV-vis studies have shown in the previous section that
triketone compounds can coordinate with metal centers and form stable complexes. The aim of
this study is to check the inhibitory activity toward oxidation generated by Cu(II)-Aβ20. From the
initial screening study of over two dozen triketone compounds, four compounds show significant
inhibition activity toward the formation of oxidized product o-quinone, which are #10, #16, #21
and #42 (Figure 3.8).
To check their activity as an antioxidant toward metal-mediated oxidation by Cu(II)-Aβ16,
different amounts of triketone compound were incubated with 1 μM of Cu(II)-Aβ20. All four
triketone compounds show various degrees of inhibiting o-quinone formation with increasing
amounts of triketone added. Due to the limited amounts sample, detailed inhibition patterns
cannot be determined; however, the Ki values of triketone #10 (Figure 3. 13) and #42 (Figure 3.
14) were obtained by fitting to competitive inhibition pattern, which is described by Equation 3.1.
Triketone #16 (Figure 3. 15) and #21 (Figure 3. 16) were fit to an uncompetitive inhibition pattern
described in Equation 3.2. The resulting Ki values for sample #10, #42, #16 and #21 are 47 μM,
132 μM, 1.9 μM and 38.8 μM respectively.
Equation 3.1
𝑡 𝑎𝑡
𝑖 𝑖𝑡
𝑖

(

)

𝑡 𝑎𝑡 𝑡

Equation 3.2
𝑡 𝑎𝑡
(

𝑖 𝑖𝑡
𝑖
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𝑡 𝑎𝑡

#10 inbition toward oxidation by 1 uM Ab20-Cu(II) in 100 mM HEPES at pH 7
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Figure 3.13: Triketone #10 inhibition toward 0.5 mM catechol oxidation by 1 μM Cu(II)-Aβ16 in
100 mM HEPES buffer at pH 7.0 and 25 ºC.
#42 inbition toward oxidation by 1 uM Ab20-Cu(II) in 100 mM HEPES at pH 7
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Figure 3.14:Triketone #42 inhibition toward 0.5 mM catechol oxidation by 1 μM Cu(II)-Aβ16 in
100 mM HEPES buffer at pH 7.0 and 25 ºC.
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#16 inbition toward catechol oxidation by 1 uM Ab20-Cu(II) in 100 mM HEPES at pH 7
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Figure 3.15: Triketone #16 inhibition toward 0.5 mM catechol oxidation by 1 μM Cu(II)-Aβ16 in
100 mM HEPES buffer at pH 7.0 and 25 ºC.
#21 inbition toward catechol oxidation by 1 uM Ab -Cu(II) in 100 mM HEPES at pH 7
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Figure 3.16: Triketone #21 inhibition toward 0.5 mM catechol oxidation by 1 μM Cu(II)-Aβ16 in
100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Curcumin Inhibition Study toward Dopamine Oxidation by Cu(II)-Aβ16

Curcumin contains a β-ketoenolate moiety, and has been shown to coordinate with several
different metal ions where the metallocurcumin complexes exhibit various kinds of biological
activity.40 Not only does curcumin act as a potent metal chelator, it also shows many biological
activities, including actin as an antioxidant. Curcumin is studied extensively for potential
therapeutic treatment, including treatments for neurodegenerative diseases, such as Alzheimer’s
disease.41
The aim of this study is to look at β-ketoenolate moiety containing compounds
acetylacetone (acac), curcumin, and demethoxycurcumin, checking their inhibitory activity
against neurotransmitter substrate dopamine oxidation mediated by Cu (II)-Aβ16.
Optical UV-Vis: to check the metal binding ability of Cu(II) to curcumin in 100 mM HEPES pH
7.5, one equivalent of Cu2+ (from CuSO4 aqueous stock) was added to 50 μM curcumin. The
Cu(II) control absorbed at 280 nm (dashed trace in Figure 3.17). Apo-curcumin has an intense
absorption around 460 nm (solid trace in Figure 3.17), and upon addition of 1 equivalenct of Cu2+,
curcumin absorption at 460 nm (dotted trace in Figure 3.17) decreases significantly while a new
complex forms around 370 nm, indicating new complex formation due to Cu(II) coordinating
with curcumin.
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Cu(II) binding to 0.05 mM curcumin 100 mM HEPES pH 7.5
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Figure 3.17: Cu(II) binding to 0.05 mM curcumin in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
The β-ketoenolate moiety of curcumin was demonstrated to be responsible for
coordinating with metal ions.42 β-ketoenolate moiety can be found in many metal binding
molecules; the simplest form is the commonly used organic compound acetylacetone, also known
as acac. In this study, acac, curcumin and demethoxycurcumin (Figure 3.18) are used as inhibitors
to inhibits the oxidation generated by Cu(II)-Aβ16.
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Figure 3.18: Chemical structures of acac, curcumin and demethoxycurcumin.

Different concentrations of acac were incubated with 0.8 mM dopamine/MBTH mixture
and 2 μM of Cu(II)-Aβ16 in 100 mM HEPES buffer solution at pH 7 to check its inhibition toward
Cu(II)-Aβ16 (Equation 3.3).
Equation 3.3

In Figure 3.19, with increasing amount of acac additions, the rate of o-quinone oxidized
product formation decreases. Hanes analysis was done to confirm the inhibition pattern (Figure
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3.20). With different concentrations of dopamine, all three concentrations in the acac traces
follow pre-equilibrium enzyme-like kinetics with catalytic parameters (Tabl 3.1). The Vmax of all
three seems to remains unchanged, while the apparent dissociation constant (Km) increase with
increasing concentration of acac; it is confirmed that acac follows a competitive inhibition pattern
toward dopamine oxidation by Cu(II)-Aβ16, which can be described by Equation 3.4 and 3.5
below:
Equation 3.4

Equation 3.5

(

𝑡 𝑎𝑡
𝑖 𝑖𝑡
)
𝑖

𝑡 𝑎𝑡

From the equation, KDopamine stands for the dissociation constant of Cu(II)-Aβ-dopamine
complex, Ki stands for the inhibition constant, where Ki is 0.49 mM in this system.
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Acetylacetone inhibition toward 0.8 mM dopamine oxidation by 2 uM Ab16-Cu in 100 mM HEPES buffer pH 7
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Figure 3.19: Acac inhibition toward 0.8 mM dopamine oxidation by 2 M Cu(II)-Aβ16 in 100 mM
HEPES buffer at pH 7.0 and 25 ºC.
Acac inhibition toward 0.8 mM dopamine oxidation by 2 uM Ab16-Cu(II) in 100 mM HEPES buffer at pH 7
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Figure 3.20: Hanes analysis of different amounts of acac inhibition toward 0.8 mM dopamine
oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Table 3.1: Catalytic parameters of different amounts of acac inhibition toward 0.8 mM dopamine
oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
Vmax (mM/s)

Km (mM)

kcat (s–1)

kcat/Km
(mM–1 s–1)

0 mM acac

(3.91±0.12)×10–6

0.36±0.05

0.0019

0.0053

(4.50±0.26)×10–6

0.84±0.12

0.0022

0.0027

(4.73±0.25)×10–6

1.12±0.14

0.0023

0.0021

(Rs=0.9954)
0.1 mM acac
(Rs=0.9959)
0.2 mM acac
(Rs=0.9972)

The inhibition activity of acac toward dopamine oxidation by Cu(II)-Aβ16 followed
competitive inhibition pattern (Figure 3.20). In order to determine the influence of curcumin on
dopamine oxidation, different concentrations of curcumin and were mixed and incubated with 2
μM Cu(II)-Aβ16 and 0.8 mM dopamine/MBTH mixture in 100 mM HEPES solution at pH 7 and
25 ºC (Figure 3.21). The reaction rate slopes of o-quinone oxidized product were measured as the
change of absorption at 500 nm as a function of time. In order to determine the inhibition pattern,
Hanes analysis was done by mixing various concentrations of curcumin and dopamine. The
results showed that all four traces of curcumin follow pre-equilibrium enzyme-like kinetics
(Figure 3.22). From Hanes analysis, the only consistent and obvious change was the apparent
dissociation constant (Km); with increasing amounts of curcumin, the Km of Cu(II)-Aβ16doapmine increasing indicating a competitive inhibition pattern, which is consistent with the acac
inhibition study (Table 3.2).
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Curcumin inhibition toward 0.8 mM dopamine oxidation by 2 uM Cu(II)-Ab16 in 100 mM HEPES pH 7
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Figure 3.21: Curcumin inhibition toward 0.8 mM dopamine oxidation by 2 μM Cu(II)-Aβ16 in
100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Figure 3.22: Hanes analysis of different amounts of curcumin inhibition toward 0.8 mM
dopamine oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Table 3.2: Catalytic parameters of different amounts of curcumin inhibition toward 0.8 mM
dopamine oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
Vmax (mM/s)

Km (mM)

kcat (s–1)

kcat/Km (mM–1s–
1

0 μM curcumin

)

(3.30±0.14)×10–6

0.29±0.04

0.0016

0.0055

(3.21±0.61)×10–6

0.34±0.02

0.0016

0.0047

(3.27±0.21)×10–6

0.61±0.13

0.0016

0.0026

(2.65±0.31)×10–6

0.80±0.24

0.0013

0.0016

(Rs=0.9893)
2 μM curcumin
(Rs=0.9959)
4 μM curcumin
(Rs=0.9972)
8 μM curcumin
(Rs=0.9972)

The inhibition ability of demethoxycurcumin was also checked against the dopamine
oxidation by Cu(II)-Aβ16. Following the same methodology as the curcumin study, by directly
titrating increasing amount of demethoxycurcumin, the oxidized product formation also decreased
(Figure 3.23). Hanes analysis (Figure 3.24) shows a decrease in Vmax and consistent increase in
Km; to further confirm the inhibition pattern, the data were replotted as a Lineweaver-Burke plot
(Figure 3.25), confirming the competitive inhibition pattern. The data were fit to a competitive
inhibition model (Equation 3.5) with a Ki value of 16.5 μM.
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demethoxycurcumin inhibition toward 0.8 mM dopamine oxidation by 2?M Cu(II)-A?16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Figure 3.23: Demethoxycurcumin inhibition toward 0.8 mM dopamine oxidation by 2 μM
Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Figure 3.24: Hanes analysis of different amounts of demethoxycurcumin inhibition toward 0.8
mM dopamine oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
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Table 3.3: Catalytic parameters of different amounts of demethoxycurcumin inhibition toward
0.8 mM dopamine oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0 and 25 ºC.
Vmax (mM/s)

Km (mM)

kcat (s–1)

kcat/Km (mM–1s–
1

0 μM

)

(2.42±0.08)×10–5

0.53±0.05

0.012

0.023

(2.13±0.03)×10–5

0.53±0.02

0.011

0.020

(1.83±0.04)×10–6

0.74±0.04

0.0091

0.012

(1.72±0.07)×10–6

1.53±0.14

0.00085

0.0005

demethoxycurcumin
(Rs=0.9980)
4 μM
demethoxycurcumin
(Rs=0.9996)
8 μM
demethoxycurcumin
(Rs=0.9994)
16 μM
demethoxycurcumin
(Rs=0.9989)
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Figure 3.25: Lineweaver-Buke plot of different amounts of demethoxycurcumin inhibition
toward 0.8 mM dopamine oxidation by 2 μM Cu(II)-Aβ16 in 100 mM HEPES buffer at pH 7.0
and 25 ºC.

Concluding Remarks: metal-mediated oxidative stress has been shown to be involved in
many neurodegenerative diseases,43 especially in the aggregation of beta-amyloid plaques in
Alzheimer’s disease.2 Previous studies have shown that Cu(II)-Aβ complex can mimic catechol
oxidase activity in generating significant amounts of oxidative stress14c, 14d which may serve an
important role in the pathology of Alzheimer’s disease. In this study, the aim is to use natural and
synthetic compounds to check their inhibitory activity toward the oxidative activity of Cu(II)-Aβ
complex. In the first part, inspired by the drug Nitisinone (NTBC) that targets the Fe(II) center in
4-HPPD enzyme for the treatment of type-1 tyrosinemia. Various derivatives of triketone
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compounds were tested against catechol oxidation by Cu(II)-Aβ complex and all showed various
degrees of μM inhibition activity. The 1H NMR and UV optical results indicate both the
kinetically active compounds and inactive compounds interact with metal-centers to various
degrees. In the second study, several β-ketoenolate-containing compounds (acac, curcumin and
demethoxycurcumin) were checked for inhibitory activity against oxidation of the
neurotransmitter substrate dopamine mediated by Cu-(II)-Aβ16. All three compounds show
inhibitory activity and the data suggests they follow a competitive inhibition pattern.
Currently, there is still no known treatment for Alzheimer’s disease and several other
neurodegenerative diseases associated with metal induced oxidative stress, such as Parkinson’s
disease. In this chapter, I have presented an assortment of synthetic and natural compounds and
shown their interaction with Cu(II)-Aβ16. The results may provide a basis for better drug design
against metal-induced oxidative stress in Alzheimer’s disease, and potentially other
neurodegenerative diseases.
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Chapter 4 Biomimetic of Cu(II)-Complexes
Introduction
Cu/O2 Chemistry

Due to the efficient electron transfer ability of Cu1+ to Cu2+, many proteins incorporate
copper at their active sites to assist a variety of important biological redox functions. Cucontaining enzymes that can bind and activate dioxygen include monooxygenases, dioxygenases,
and oxidases, and different examples of them are provided in Figure 4.1. Dioxygenases are
enzymes that can incorporate both oxygen atoms into the products while monooxygenases only
incorporate one oxygen atom of O2 into a substrate and the other oxygen is further reduced to a
water molecule. Oxidases catalyze oxidation reactions of various substrates with reduction of both
oxygen atoms of O2 into water molecules.1

Figure 4.1: Examples of O2 activation by Cu enzymes and proteins.2
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The coordination environments of these Cu-containing enzymes are strongly associated
with their functions. By looking at the active site environment, it can provide great insight into
designing potent catalysts that mimic biological redox activities. Many of the ligands that present
in the active sites contain aromatic nitrogen-containing aromatic rings like pyridine, imidazole
and pyrazole. Thioesther and disulfide groups can use sulfur for coordination and phenolate ions
offer good oxygen ligation.2 The presence of one or more than one five- or six-member rings at
the active site stabilize and promote metal complex binding.2
The general proposed mechanism of dioxygen binding to mononuclear copper center is
described in Figure 4.2. In this process, dioxygen bind to the Cu(I) center and form a 1:1 LCu/O2
complex, and this adduct can sometimes bind with a second Cu complex to form binuclear
species. There are several modes of dioxygen binding to mono-, di- and tri-copper center and they
were discussed in chapter one. In this section, the catalytic activity of Cu/O2 proteins will be
briefly discussed. 3

Figure 4.2: General proposed mechanism of Cu/O2 binding.
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Most of the kinetic studies done on 1:1 Cu/O2 used stopped-flow kinetics as short-live
intermediate, and at the next step form more stable 2:1 Cu/O2 complexes.4 The dissociation
constant K1 for the formation of 1:1 and 2:1 Cu/O2 adduct at low temperatures of different Cu(I)
complexes in ethanol are shown in Table 4.1 and Table 4.2.
Table 4.1:Selected kinetic parameters for the formation of 1:1 Cu/O2 adducts upon low
temperature oxygenation of Cu(I) complexes.3
Ligand

k1(M–1 s–1)

k–1(M–1 s–1)

K1(M–1)

TMPA

(1.18

0.01)×104

15.9 ± 0.1

(7.24 0.04) ×102

4OMe-TMPA

(1.93

0.04)×104

1.11 ± 0.06

(1.73 0.08) ×104

TMPAE

(1.18

0.01)×103

29 ± 2

(2.84 0.09) ×102

(6.1 ± 0.7) ×10–3

(2.9 0.3) ×103

BQPA

18

1
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Table 4.2: Selected kinetic parameters for the formation of 2:1 Cu/O2 adducts upon low
temperature oxygenation of Cu(I) complexes (See Table 4.1 for ligand structure).3
Ligand

k2(M–1 s–1)

k–2(M–1 s–1)

TMPA

(1.34

0.02)×104

(2.0

4OMe-TMPA

(1.85

0.01)×104

(8

TMPAE

0.05

BQPA

N/A

(2.1

0.2)×10–5
0.2)×10–6
0.4)×10–5
N/A

K2(M–1)
(6.7 0.7) ×108
(2.4 0.7) ×109
(7 2) ×105
(2.0 0.2) ×103

One of the type-3 Cu/O2 enzymes catechol oxidase is responsible for catalyzing various
catechols into o-benzoquinone products, which may undergo auto-polymerization to form
melanin, a brownish pigment. In Chapter one, the mechanisms and binding mode of Cu complex
with catechol were discussed. The active site of the enzyme contain three histidine residues on
each Cu. Oishi et al, reported higher DTBC oxidation activity of di-nuclear Cu(II) complexes
compared to the mononuclear complexes.5 The results were consistent with the hypothesis of the
formation of di-nuclear intermediate, di-Cu(II)-catechol.6 The distances between the two Cu(II)
centers in di-copper complexes correlate with their catalytic ability. If the distance between the dicopper centers is longer than 5 Å, the catalytic ability of the complex decrease to minimum.7 The
generation of hydrogen peroxide was reported during catechol redox cycle, and Chyn and Urbach
had proposed possible mechanism for the generation (Figure 4.3).8 In most of the copper(II)
complexes that mimic catechol oxidase activity, a Michaelis-Menten kinetic model can be used to
describe how the system behave. In most of the Cu(II)-containing complexes that mimic catechol
oxidases, the apparent dissociation constants (Km) vary in the range of 10–4 to 10–3 M and the first
order rate constants (kcat) are in the range of 10–2 to 10–1 s–1 . On top of that, in most of the
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situation, a first-order linear dependence of reaction rate is observed with increasing concentration
of the catalyst.9 In general, hydrogen peroxide can participate in the catalytic cycle by reoxidizing
the reduced di-Cu(I) complexes to Cu(II) and competing with dioxygen. The presence of
hydrogen peroxide can change the rate-determining step in the reaction at higher concentration of
hydrogen peroxide. Enhancement of catalytic rate is also observed in some systems with the
presence of hydrogen peroxide, while in some systems, it does not seem to influence the rate
much.10 Furthermore, with increasing amounts of hydrogen peroxide, a saturation behavior of
reaction rate is observed.11

Figure 4.3: Possible mechanistic pathway in the formation of H2O2 as a by-product.12
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The Role of Histidine in Biological Systems

Histidine is observed commonly in many metalloenzymes’ active sites as a coordinating
ligand. The histidine side chain contains a five-membered imidazole ring with two nitrogen atoms
on it which act as potential metal binding sites. The structure of imidazole is analogues to the
structures of pyridine and pyrrole (Figure 4.4).

Figure 4.4: Chemical structures of histidine, pyrrole, imidazole and pyridine.
The interaction of transition metal ions with the histidine side chain in biological systems
has gained lots of attention. The imidazole on histidine side chain provides many opportunities for
the peptides/proteins to interact with different metal ions. There are three potential metal binding
sites for the amino acid histindine depending on the pH: the first pKa is the carboxyl group (pKa=
1.9), followed by the imidazole nitrogen (pKa=6.1) and finally the amino nitrogen (pKa=9.1),
where the imidazole ring is usually under half-deprotonated state in physiological condition
(pKa~7.4) where NƐ (the pyridine-like nitrogen) is deprotonated before than Nδ (the pyrrole-like
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nitrogen). Both of these N-sites on the imidazole ring can potentially coordinate with metal ions,
but the Nδ is less favorable based on existing known protein structure compared to NƐ.13
Histidine can also coordinate with metal ion through the N-terminus. Aqueous Cu(II)-His
model has been studied extensively and different pH-dependent Cu(II)-His species were reported
(Figure 4.5).

Figure 4.5: Possible modes of Cu(II)-His coordination (protonated and deprotonated). Adopt
from Burger. 14

162

Peptoid Chemistry

Peptoids, also known as poly-N-subsituted glycines, are one of the novel inventions in the
category of peptidomimetics. The general structure of peptoids is very similar to peptides (Figure
4.6) and the main difference is the location of the side chains. In a peptide structure, the side chain
is connected to the α-carbon atom, while in a peptoid structure, the side chain is connected to the
nitrogen atom on its backbone.15 Peptoids can include various amino acid residues as side chains
for specific chemical interactions and biomolecular recognitions. They are sequence-specific like
peptides. Furthermore, many peptoids can be synthesized efficiently, which allow researchers to
build a compound library using peptoid oligomers for various chemical systems, including drug
discovery and material science.

Figure 4.6: Backbone structure of peptide and peptoid.

Due to the structural modification, peptoids tend to lack the ability to form backbone
hydrogen bonds and are less likely to form secondary structures as well. However, through
careful design there have been reports of self-assembling peptoids forming secondary structures
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like helix turns, and was investigated through various physical methods including NMR, circular
dichroism (CD) and X-ray crystallography.15-16 Like many D-peptides and β-peptides, peptoids
are not easily degraded by peptidases and proteases, allowing peptoids to serve as therapeutic
agents with higher bioavailability.17 Many reports have suggested the ability of peptoids to exhibit
various biological activities. Studies have shown that peptoid oligomers are excellent protein
binding ligands.18 For example, a cationic 36-mer peptoid was shown to bind to DNA while
shielding DNA from nuclease digestion while also promoting gene transfection.16d Studies have
also demonstrated the ability of peptoids to bind to integral membrane receptors and behave like
antibodies. For example, in both in vitro and in vivo studies, a dimer derivative of peptoid was
found to act as an antagonist toward vascular endothelial growth factor receptor 2 (VEGFR2).19
Due to the versatile structures and ability to interact with many proteins, the potential applications
of peptoids can be wide and impactful.
There have been many efforts into biocompatible designing of the ideal synthetic chemical
catalysts. Metal ions play important roles in various biological activities including electron
transfer, signaling transductions and catalysis. Many enzymes catalyze specific reactions utilizing
metal centers as co-factors. For example, superoxide dismutase (SOD) catalyzes the conversion of
superoxide to dioxygen and hydrogen peroxide, where the active center contains both Cu and
Zn.20 Lately, there has been a lot of research toward using peptides and peptoids-based structures
in designing biocompatible material. Peptoid is an excellent platform to develop due to its
versatile functions. Furthermore it can be synthesized efficiently using primary ammines in solidphase technique sites.15 The side chains of peptoids, can interact with many targets through
various chemical interactions including electrostatic, hydrophobic, hydrophilic, aromatic stacking
and hydrogen bonding. Peptoids have the ability to coordinate with metal ions through their
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Lewis base donor side chains such as histidine, glutamic acid, tyrosine and cysteine under
deprotonated conditions, demonstrating various biological activities. Studies have shown peptoid
can form secondary nanostructures through binding with metal centers such as Zn(II), Co(II) and
Cu(II) to exhibit potential catalytic activities.21

Material and Methods
All reagents and solvents were commercially available from Sigma Aldrich and Fisher.
Aqueous solutions were prepared from 18 MΩ deionized water.
Kinetics Study

Cu(II) complex of a multidentate cyclophosphazene with imidazole-containing side chains
(CpzIm6) and its catechol oxidation activities: CpzIm6 sample was obtained through collaboration
with Dr. Wang Le and was synthesized following a previously established method [13]. Stock
solution of CpzIm6 was prepared in methanol. The 50% methanol/HEPES buffer solutions were
prepared by directly mixing equal amounts of methanol to 100 mM HEPES buffer solution at pH
7.5. Catechol, dopamine and MBTH were dissolved in D.I. water while DTBC and phenol were
prepared in methanol. 1-5 μM of

-(CpzIm6) were incubated with substrate and their

corresponding oxidized product formation rates were measured at change in absorption as a
function of time in either 100 mM HEPES buffer pH 7.5 or 50% methanol/HEPES buffer
solutions at 25 ºC. The molar absorptivity of oxidized products of catechol/MBTH,
dopamine/MBTH, phenol and DTBC were used to solve the rates (Ɛ= 32500 M–1 cm–1 for
catechol/MBTH, 27200 M–1 cm–1 for dopamine/MBTH, Ɛ= 1740 M–1 cm–1 for DTBC).
Short peptoid: The peptoid γ-AA-FHFH sample was provided by Dr. Cai at University of
South Florida, and the synthesis method has been reported.
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γ-AA-FHFH was dissolved in

methanol and its concentration was determined by the molar absorptivity of phenylalanine moiety
at 257 nm (Ɛ = 200 cm–1M–1). 3,5-di-tert butyl catechol (DTBC) was dissolved in methanol. 5 μM
of γ-AA-FHFH was incubated with different concentrations of DTBC, and the formation of the
DTBQ oxidized product formation was measured as a function of time in methanol at 25 ºC (Ɛ400=
1910 M–1 cm–1 for DTBQ).
NMR Study

The 1H NMR spectrums of apo-Ac-FHFH peptide, apo-γ-AA-FHFH, as well as their
Co(II) complexes were collected on INOVA 600 MHz NMR spectrometer with a triple resonance
probe. Both apo-Ac-FHFH peptide and apo-γ-AA-FHFH were dissolved in methanol to determine
the stock solution concentrations, by the use of the phenylalanine molar absorptivity at 257 nm (Ɛ
= 200 cm–1M–1). Aliquots were taken from the apo Ac-FHFH peptide and apo-γ-AA-FHFH stock
solutions, then diluted to 4 mM in 500 μL d4-methanol 5-mm NMR tube. CoCl2 was used as the
Cu(II) ion source and was prepared in d4-methanol solution. The Cu(II)-Ac-FHFH peptide and
Cu(II)-γ-AA-FHFH complexes were prepared by directly adding one equivalence of Cu(II)
solution to prepared peptides. Two equivalence of triethyamine(TEA) was added to each 4 mM
sample to promote Cu(II) binding to the imidazole moieties.

Results and Discussion
Cu(II) Complex of a Multidentate Cyclophosphazene with Imidazole-containing Side Chains and its
Catechol Oxidation Activities

In this study, the oxidation activity of a multidentate cyclophosphazene with six
imidazole-containing side chains (Figure 4.7) was investigated. A multinuclear catalyst was
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assembled from the ligand that contains multiple potential metal binding sites, allowing metal to
coordinate and act as the redox active sites.

Figure 4.7: Chemical structure of CpzIm6.
Cyclophosphazene is a planar ring that consists of alternating nitrogen and phosphorus on
the conjugated ring.23 Each phosphorus on the ring extends out with imidazole containing arms
providing potential metal binding sites mimicking the histidine moiety in the active site of many
enzymes. In this study, a macrocyclic multidentate cyclophosphazene with imidazole containing
side chains compound was complexed with Cu(II) ions to mimic type 3 dioxygenase activities.
This compound was previously demonstrated in UV-vis to bind up to three Zn(II) ions, and the
EPR results suggested CpzIm6 can also form up to 3 Cu(II) ions.24 and the aim of this project is to
investigate the complex catalytic ability against several phenol and catechol containing substrates
by the use of kinetics.
To check the oxidation catalytic activity of Cu3-(CpzIm6) toward different substrates
including catechol, 3,5-di-tert butyl catechol (DTBC), dopamine and phenol, 1-5 μM of
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-

(CpzIm6) solutions were incubated with different concentrations of each substrate. The o-quinone
oxidized products of catechol, dopamine and phenol were captured with MBTH as a dye, forming
a pinkish-red product with an absorption peak at 500 nm. The quinone oxidized product of DTBC
showed up at 410 nm. The initial rates of substrate oxidation by 1-5 μM of Cu(II)3-(CpzIm6) were
measured in 100 mM HEPES buffer pH 7.5 at 25 ºC for catechol, dopamine and phenol oxidation
(Ɛ= 32500 M–1 cm–1 for catechol and phenol MBTH adducts, Ɛ= 42500 M–1 cm–1 for dopamine
MBTH adduct, Ɛ= 1910 M–1 cm–1 for DTBC). Due to the low solubility of DTBC in aqueous
environments, methanol (MeOH) was mixed with 100 mM HEPES buffer at pH 7.5 in a 1:1 ratio
and used as the solvent. Upon increasing amounts of substrate, there was an increase in initial
oxidation rate. At higher substrate concentrations, the rates eventually reach a plateau, indicating
a pre-equilibrium enzyme-like kinetic pattern. The catalytic reaction can be described as Equation
4.1. The initial rates at various substrate concentrations were plotted and fit to Equation 4.2 to fain
the kinetic constant of kcat and Km (Table 4.1).
Equation 4.1

Equation 4.2
𝑅𝑎𝑡

(

All four substrates follow pre-equilibrium enzyme like kinetics and afford kcat values of
4.2×10–2, 5.0×10–3, 4.8×10–4 and 1.2 ×10–4 s–1 respectively for DTBC, catechol, dopamine and
phenol respectively (Figure 4.8, 4.19, 4.10 and 4.11). Catechol and dopamine had relatively small
apparent dissociation constants and of 0.07 mM, and 0.04 mM respectively. In comparison, the
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apparent dissociation constants for phenol and DTBC are 0.99 mM and 5.84 mM respectively
indicating a less stable intermediate complex of [

-(CpzIm6)-S] complex. To compare the

overall kcat/Km catalytic efficiency values, catechol had the highest kcat/Km among all four
substrates followed by dopamine, DTBC and phenol having the lowest kcat/Km values of 1.2×10–4
s –1 mM–1 (Table 4.3).
Table 4.3: Catalytic parameters for different substrates of Cu(II)3-CpzIm6 oxidation.
Vmax(mM/s)

Catchol(Rs=0.9969)

(5.13±0.10)×10

DTBC(Rs=0.9956)

(4.20±0.22)×10

Dopamine(Rs=0.9858) (2.38±0.08)×10
Phenol(Rs=0.9877)

(6.03±0.04)×10

–6

–5

–6

–7

–1

Km (mM)

kcat (s )

0.07±0.01

5.0×10

5.84±0.65

4.2×10

0.040±.007

4.8×10

0.99±0.22

1.2×10
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–3

–2

–4

–4

kcat/Km(s–1
mM–1)
7.3×10
7.2×10
1.2×10
1.2×10

–2

–3

–2

–4

Catechol oxidation by 1 uM Cu3-(CpzIm6) in 100 mM HEPES buffer at pH 7.5
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6e-6

4e-6

2e-6

0
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[Catechol] mM

Figure 4.8: Catechol oxidation by 1 μM

-(CpzIm6) in 100 mM HEPES buffer at pH 7.5 at
25 ºC.

Dopamine oxidation by 5 uM Cu3-(CpzIm6) in 100 mM HEPES buffer at pH 7.5
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1e-6
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Figure 4.9: Dopamine oxidation by 5 μM

-(CpzIm6) in 100 mM HEPES buffer at pH 7.5 at
25 ºC.
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DTBC oxidation by 1 uM Cu3-(CpzIm6) in 50/50 MeOH/100 mM HEPES buffer at pH 7.5
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Figure 4.10: DTBC oxidation by 1 μM
-(CpzIm6) in 50/50 MeOH/100 mM HEPES buffer
at pH 7.5 at 25 ºC.

Phenol oxidation by 5 uM Cu3-(CpzIm6) in 100 mM HEPES buffer at pH 7.5
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Figure 4.4: Phenol oxidation by 5 μM

-(CpzIm6) in 100 mM HEPES buffer at pH 7.5 at 25
ºC.
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For the Cu(II) dinuclear complex oxidation mechanism, there are two possible pathway
for the redox cycle. The data shows that Cu(II) dinuclear complex can perform oxidation
chemistry in the air by the use of O2 as the oxidation agent, where substrate binds directly to the
Cu(II) center and gets oxidized, followed by releasing the first oxidized product, which in turn
reduces both copper center to Cu(I). Once the metal center was reduced to Cu(I), it allowed the
dioxygen molecule to bind, forming peroxyl bridging intermediate and allowing a second
substrate to bind and oxidized. Hydrogen peroxide can participate in redox pathways and is a
strong oxidizing agent. In the case of tyrosinase, it can interact with the met-form of the dinuclear
copper centers, where dioxygen cannot. In the alternative pathway, with presence of hydrogen
peroxide, the H2O2 can directly bind to the Cu(II) center without reduction to Cu(I). Once H2O2 is
coordinated to the metal center, the intermediate formed and can rearranged, allowing substrate
binding. Figure 4.12 shows the capability of the complex to interact with H2O2 was with 1 mM
catechol in 100 mM HEPES buffer solution at pH 7.5 and 25 ºC. As the concentration of H2O2
increased, the peroxidation rate increased initially and reached saturation around 200 mM H 2O2,
indicating hydrogen peroxide directly binding to di-Cu(II) center to form a di-Cu(II)-peroxy
intermediate which allows catechol to bind and produce oxidized quinone. The data was fit to
Equation 4.3, where S is H2O2, affording kcat and Km parameters to be 0.05 s–1 and 132 mM, and
kcat/Km of 4.0×10–4 mM–1 s–1. The kcat/Km without peroxide is 7.3×10–2 mM–1 s–1 which is 182-fold
higher than peroxidation. The results showed that the

-(CpzIm6)complex can interact with

both catechol and hydrogen peroxide, making it a bi-substrate system.
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Peroxidation by 1 uM Cu(II)3-CpzIm6 with 1 mM catechol in100mM HEPES at pH 7.5
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Figure 4.5: Peroxide saturation of 1 μM
-(CpzIm6) and 1 mM catechol in 100 mM HEPES
buffer at pH 7.5 at 25 ºC.

Equation 4.3

Since

-(CpzIm6) can bind to both substrates catechol and hydrogen peroxide, and

exhibit pre-equilibrium kinetic patterns and interact with the metal center differently, the system
can be considered as a bi-substrate system and be investigated through Hanes analysis. To further
understand the interaction between catechol and hydrogen peroxide toward Cu(II) metal center,
several concentrations of hydrogen peroxide were incubated with various concentrations of
catechol to determine the reaction rates by 1 μM of

-(CpzIm6) in 100 mM HEPES buffer at

pH 7.5 in 25 ºC, and their oxidation rates were measured (Figure 4.13). The data were plotted and
processed through Hanes analysis, confirming the system followed a random bi-substrate
mechanism where both catechol and peroxide can independently form intermediates and going
through redox cycles. In Figure 4.14, the data was reprocessed and plotted as
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against

[catechol] (Figure 4. 14), and the y-intercepts (Figure 4.15 left ) and slopes (Figure 4.15 right)
were plotted against

. Through Equation 4.4, 4.5 and 4.6, the apparent and intrinsic

dissociation constants:

,

and

were calculated and are 12, 9.93 and 0.36 mM,

representing the dissociation constant of (

(

(

and

(

𝑐𝑎𝑡 𝑐

respectively (Table 4.2). From the ratio of the

,
𝑐𝑎𝑡 𝑐

, it can provide information of how one

substrate’s binding ability is affected with the presence of the other substrate. The

ratio of

H2O2 is 1.20 and 5.14 for catechol; the ratios indicated both substrates are influenced by each
other’s presence. Especially for catechol, it was affected twice as much by the presence of H2O2
than H2O2 was affected by the presence of catechol.
Catechol oxidation by 1uM Cu(II)3-CpzIm6 in the presence of different
concentration of H2O2 pH 7.5 100mM HEPES buffer
8e-5
0mM H2O2
20mM H2O2
40mMH2O2
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Rate (mM/s)

6e-5

4e-5

2e-5

0
0

1

2

3

[Catechol] mM

Figure 4.6: Hanes analysis of catechol oxidation by 1 μM Cu(II)3-CpzIm6 with different amounts
of H2O2 in 100 mM HEPES buffer at pH 7.5 at 25 ºC.
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Equation 4.4
(

𝑐𝑎𝑡 𝑐

)
𝑐𝑎𝑡 𝑐

(

)(

)

Equation 4.5
𝑖 𝑡 𝑐 𝑝𝑡

(

)

Equation 4.6
𝑝

(

)

Hanes analysis of the oxidation of catechol by Cu(II)-CpzIm6 at different
concentrations of H2O2
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Figure 4.7: Hanes analysis of the oxidation of catechol by Cu(II)3-CpzIm6 at different
concentrations of H2O2 (Reprocessed data from Figure 4.13)
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Figure 4.8: Replots of the y-intercept (left graph) and slope (right graph) values from Figure 4.14
with respect to [H2O2].
Table 4.4: Apparent and intrinsic dissociation constants from Hanes analysis
Kapp (mM)

Kint (mM)

Kapp/Kint

H2O2

12

9.93

1.28

Catechol

0.36

0.07

5.14

Short Peptoid Metal Binding and Catalysis

In order to understand the detailed mechanisms of various biological pathways,
developing novel peptidomimetics and small molecules that can mimic protein-protein interaction
in cellar process is extremely crucial. The newly designed γ-AApeptides were prompted by the
scheme of the peptoid backbone structure, and further incorporating the concept of chiral peptide
nucleic acid backbones, including N-acyl-N-aminoethyl amino acid moieties. The overall
structural framework of γ-AApeptides is similar to the natural α-peptides containing both α-amino
side chain and a carboxylic acid moiety connected to the tertiary amide nitrogen.25 As a result of
the structural modification, peptoids can have the same number of side chain amino acids and
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same backbone length as α-peptides. Previous studies have demonstrated the ability of AApeptide
derivatives forming secondary novel nanostructures26, acting as antimicrobial agents and binding
to RNA.27 It was demonstrated that γ-AApeptide can bind to the TAR RNAs of HIV and BIV,
mimicking the activity of the HIV-1 Tat protein.27a The lipo-γ-AApeptides derivatives showed
inhibition activity toward fungi (Candida albicans), Gram-positive (Escherichia coli, Klebsiella
pneumoniae and Pseudomonas aeruginosa) and Gram-negative bacteria (Bacillus subtilis,
Staphylococcus epidermidis, Enterococcus faecalis and Staphylococcus aureus) and can
potentially be used as board-spectrum antibiotics.27c
Metal ions play important roles in biological systems by performing various activities at
the metal centers. Transition metal ions such as Cu(II) and Fe(III) can go through redox cycles
efficiently. Therefore, to further functionalize γ-AApeptide, the structure and activity study of a
short sequence metallo-γ-AApeptide, Cu(II)-γ-AA-FHFH, was investigated in this project, which
demonstrated the ability of metallo-γ-AApeptide to act as a new class of peptidomimetic catalysts.
The structures of γ-AA-FHFH and Ac-FHFH are shown in Figure 4.16 where both sequences
contain two histidines and two phenylalaines with backbone variations. The imidazole moiety on
His is designed to act as a potential metal binding site.
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Figure 4.9: Chemical structures of γ-AA-FHFH and Ac-FHFH
UV-vis results: the imidazole moiety on histidine can be found in the active sites of many
enzymes and participate in the coordination with metal ions. In this short γ-AApeptide, we
incorporated two histidines into the sequence, allowing Cu(II) to coordinate with and further act
as a redox center for catalysis. To investigate the metal binding ability of γ-AA-FHFH, 0.146 mM
of γ-AA-FHFH was dissolved in methanol with two equivalents of triethylamine(TEA) added to
ensure full-deprotonation on the potential metal binding sites of histidines. The apo-γ-AA-FHFH
spectrum was collected in the range of 200 to 800 nm with no distinct absorption other than a
peak around 260 nm in methanol. Upon Cu2+ (from CuSO4) titrations, a new absorption band
formed around 342 nm and eventually reached saturation. The absorbance values of each addition
at 342 nm were plotted against the equivalent of Cu(II) additions. A control of CuSO4 was
performed and the corresponding UV absorption at 342 nm to Cu

2+

equivalence was plotted with

Cu(II)-γ-AA-FHFH. The results showed a turning point around half equivalence of Cu(II),
suggesting a metal to ligand ratio of 1:2 binding stoichiometry (Figure 4.17)
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Figure 4.9: Cu(II) titration to 0.146 mM γ-AA-FHFH

Paramagnetic NMR is a great tool for elucidating the peptide/protein structures and
coordination environment upon metal binding. In this section, Co(II) was used as a probe for
Cu(II) in monitoring metal binding by means of

1

HNMR since Co(II) has a fast electronic

relaxation and can afford characteristic hyperfine-shifted signals in the paramagnetic region upon
its binding to peptides.28 To probe the metal binding of both Ac-FHFH and γ-AA-FHFH, Co(II)
was added to 4 mM of Ac-FHFH (Figure 4.18: top spectrum) and γ-AA-FHFH (Figure 4.18:
bottom spectrum). To see the solvent exchangeable signal, methanol was added to 4 mM of AcFHFH (Figure 4.18 middle) and the resulting 1H NMR spectrum of show a few paramagnetically
shifted signals within the region of 100 ppm. Paramagnetically shifted signals are due to unpaired
electron in metal complexes, wherein, protons near the metal-binding site will be affected the
most and tend to be boarder, compared to protons that are farther away from the metal center.

179

In the spectrum of Co(II)-Ac-FHFH in d4 methanol (Figure 4.18 top), it seems to have two
sets of signals at 55, 57, 65 and 71 ppm, suggesting Co(II) coordinating to imidazole moiety in
both His. The paramagnetically shifted-signals are consistent with signals from paramagnetic
metal binding to histidine like the case of Co(II)-substituted Cu, Zn-SOD, in which the active site
consists of Cu(II) and Co(II) coordinating to histidine moieties affording paramagnetically shifted
signals in the range of 35 to 65 ppm.29 The two sets of signals have relatively similar half-peak
widths and intensity, suggesting Co(II) binding through the Ɛ-nitrogen on imidazole (Figure 4.18).
Such NƐ-coordination mode would render the CδH and CƐH protons at the ortho positions to the
metal and exhibit relatively broad signals. The NδH protons are not seen in the complex in d4methanol due to exchange with the solvent. To reveal the solvent exchangeable signal, upon
addition of 250 μL of CH3OH, the two NH signals become detectable appearing at 75 and 77
ppm, confirming that Co(II) binding to the two histidine residues (Figure 4.18 middle spectrum).
In the bottom spectrum of Figure 4.18, Co(II)-γ-AA-FHFH afford two sharp shifted
signals in the region of 40 to 70 ppm and a board signal at 96 ppm. The chemical shift region of
where the two sharp signals appeared are consistent with histidine binding to Co(II)29a. However,
the board signal ~96 ppm remains unclear.
There are two hypothesis when it comes to Co(II) binding to histidine residues. First,
assuming Co(II) binds to both of the Ɛ-nitrogen on imidazole ring, we should expect seeing two
sets of two board signals, and one solvent exchangeable signal from δ-nitrogen which disappear
when added D2O. However, the two shifted signals are too sharp to support the hypothesis of
Co(II) binding to Ɛ-nitrogen. Another possibility is that Co(II) is binding through both δ-nitrogen
on imidazole, we should expect to see two board CƐH signal and a sharp CδH signal in addition to
a solvent exchangeable NƐH signal on imidazole ring will disappear when added D2O. From the
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spectrums, the data cannot lead to a conclusion of the exact metal binding site of γ-AA-FHFH.
Further 1D and 2D techniques will help to elucidate the coordination site of Co(II) binding to γAA-FHFH.

Figure 4.10:1H NMR of Co(II)-Ac-FHFH (top spectrum), Co(II)-Ac-FHFH with solvent
exchangeable signal (middle spectrum) and Co(II) γ-AA-FHFH (bottom spectrum) in d4-methanol.
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To test the ability of Cu(II)-γ-AA-FHFH to catalyze oxidation and peroxidation activity,
3,5,di-tert-butyl catechol (DTBC) was used as the substrate to monitor the formation of the
oxidized product di-tert-butyl quinone formation. Since Cu(II) can potentially coordinate to more
than one γ-AA-FHFH, both 1:1 and 1:2 Cu(II):γ-AA-FHFH complexes were prepared in
methanol by direct addition of metal to peptoid. The concentration of γ-AA-FHFH solution was
determined by the absorption at 257 nm (Ɛ =200 cm–1 M–1) attributed from phenylalanine side
chain. The yellowish oxidized product di-tert-butyl quinone showed up at 400 nm and the product
formation over time was monitored. Different concentrations of DTBC were incubated with 5 μM
of complex in methanol at 25 ºC (1:1 or 1:2 Cu(II):γ-AA-FHFH). With increasing amounts of
DTBC (Figure 4.19), the initial rates increase for both complexes, followed by a plateau,
indicating that both 1:1 and 1:2 complexes exhibit pre-equilibrium-like kinetics, as described
below (Equation 4.7)
Equation 4.7

Equation 4.8

Equation 4.9

The data was fit to a hyperbola-derived equation (Equation 4.8), providing catalytic
parameters Vmax and Km. Vmax describes the rate at maximum activity and V0 describes the
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measured rate of the activity. Km, the apparent dissociation constant of substrate-bound complex,
[DTBC-Cu(II)-γ-AA-FHFH which can be described as Equation 4.9. From the fitted data, the 1:1
Cu(II):γ-AA-FHFH complex has a higher first-order rate constant, kcat = 0.012 mM, which is 10fold higher than the 1:2 Cu(II):γ-AA-FHFH complex kcat of 0.0011 mM. This can be explained by
the availability of Cu(II) coordination sites; Cu(II) has a d9 electron configuration and has six
open coordination sites which allow ligands to bind. For the 1:1 Cu(II):γ-AA-FHFH complex,
where one γ-AA-FHFH coordinates to one Cu(II) ion center through two nitrogens from histidine
side chains. DTBC binds to the Cu(II) center through the remaining two open coordination sites,
allowing the complex to go through redox. For the 1:2 Cu(II):γ-AA-FHFH complex, with two γAA-FHFH and one catechol binding to the Cu(II) center, there is no open coordination site to
facilitate the redox cycle that also requires oxygen binding, which lead to lower turnover rate of
o-quinone formation. The apparent dissociation constants were similar (0.17 and 0.22 mM
respectively) for 1:1 Cu(II):γ-AA-FHFH and 1:2 Cu(II):γ-AA-FHFH. The catalytic efficiency
(second-order rate constant) of the complexes of 1:1 and 1:2 complexes can be described as kcat/Km were 0.07 mM and 0.005 mM, respectively.
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DTBC oxidation by complexes in methanol
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Figure 4.19: DTBC oxidation by 5 μM 1:1 Cu(II):γ-AA-FHFH and 1:2 Cu(II):γ-AA-FHFH in
methanol at 25 ºC.
Table 4.5: Catalytic parameters from DTBC oxidation by 5 μM 1:1 Cu(II):γ-AA-FHFH and 1:2
in methanol at 25 ºC.
kcat/Km
Vmax (mM/s)
1:1 no

-1

-1

kcat (s )

(s mM )

–

0.17±0.02

0.012

0.070

–6

0.21±0.02

0.0011

0.005

(6.22±0.23)×10–5

peroxide
(Rs=0.9909)
1:2 no

(5.35±0.01)×10–6

-1

Km (mM)

peroxide
(Rs=0.9980)
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In the proposed mechanism of oxidation by Cu(II) peptide complex, there are two possible
pathways. The first pathway starts off with a substrate binding to Cu(II) centers, releasing a
semiquinone product, then further reducing to Cu(I), allowing O2 to bind and form intermediates
and continue through redox cycles. The second pathway involves the participation of hydrogen
peroxide, which can directly bind to the Cu(II) centers, forming highly active η2 side-on binding
intermediates and continue through redox cycles efficiently. There are three possible forms of
intermediates including Cu(II)-superoxo (-O2–), Cu(II)-hydroperoxo (-OOH) and Cu(III)-peroxo
(-O22–).30 Due to the steric hindrance in the active site, the side-on mode of Cu (II)-superoxo and
Cu(II)-hydroperoxo are more likely to be the active intermediate.
Cu(II):γ-AA-FHFH complexes have been demonstrated to have the ability to mimic
catechol oxidase going through oxidation. Usually with the presence of hydrogen peroxide, the
oxidation rate can be enhanced due to the direct formation of highly active intermediates. The
ability of 1:1 Cu(II):γ-AA-FHFH complexes to perform peroxidation was investigated by
incubating different concentrations of hydrogen peroxide with 5 μM of 1:1 complex and 0.3 mM
DTBC in methanol. With increasing amount of H2O2 added, the peroxidation rate increased
initially and the activity remained similar at higher concentrations of H2O2 (Figure 4.20). To
indicated Cu(II):γ-AA-FHFH complex followed pre-equilibrium enzyme-like kinetics performing
peroxidation chemistry. The reaction afforded first order rate constant of kcat 0.1 s–1, apparent
dissociation constant Km of 8.50 mM and kcat/Km of 0.012 s–1mM–1 (Table 4.4).

185

Peroxidation activity by 5 uM 1:1 Cu(II):AA-FHFH and 0.3 mM DTBC in methanol
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Figure 4.20: Peroxidation saturation of 5 μM 1:1 Cu(II):γ-AA-FHFH with 0.3 mM DTBC in
methanol at 25 ºC.

Table 4.6: Catalytic parameters of peroxide saturation by 5 μM 1:1 Cu(II):γ-AA-FHFH with 0.3
mM DTBC in methanol at 25 ºC.
kcat/Km
Vmax (mM/s)
1:1

(5.0±0.1)×10–4

–

-1

-1

-1

Km (mM)

kcat (s )

(s mM )

8.50±0.84

0.1

0.012

(Rs=0.9982)
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In order to further understanding how Cu(II):γ-AA-FHFH complexes behave with the
presence of hydrogen peroxide, 2 mM fixed amounts of hydrogen peroxide were added to 5 μM
of 1:1, 1:2 and 1:3 Cu(II):γ-AA-FHFH complexes with increasing amount of substrate DTBC
(Figure 4.21, 4.22 and 4.23). With 2 mM hydrogen peroxide presence, all three traces followed
pre-equilibrium enzyme-like kinetic activity and can be fitted well to Equation 4.8. 1:1 and 1:2
Cu(II):γ-AA-FHFH complexes behaved similarly toward DTBC oxidation with the presence of
hydrogen peroxide, with both affording first order rate constants (kcat) of 0.04 s–1, and much
smaller apparent dissociation constants (Km) compare to the values without hydrogen peroxide.
The results suggested that with the presence of hydrogen peroxide, the binding of Cu(II):γ-AAFHFH to DTBC was enhanced in both 1:1 and 1:2 complexes (Table 4.5). For the 1:1 Cu(II):γAA-FHFH complex, the Km value decreased 4-fold in the case of peroxidation (Km = 0.042 mM)
compared to oxidation (Km = 0.17 mM), and for the 1:2 Cu(II):γ-AA-FHFH complex the Km
value decreased 7.2-fold in the case of peroxidation (Km = 0.029 mM) compared to oxidation (Km
= 0.21 mM). The resulting ratio of kcat/Km of 1:1 and 1:2 Cu(II):γ-AA-FHFH complexes toward
peroxidation are 0.94 s–1 mM–1and 1.38 s–1 mM–1respectively, which are much higher than the
kcat/Km values of oxidation. 1:1 Cu(II):γ-AA-FHFH complex showed selectivity toward
peroxidation with 14-fold increase in kcat/Km compared to oxidation activity, and in the case of
1:2 Cu(II):γ-AA-FHFH complex, it showed even more drastic increase in selectivity toward
peroxidation affording 272-fold increase in catalytic efficiency compared to oxidation Comparing
the catalytic parameters from both 1:1 and 1:2 complexes towards oxidation and peroxidation,
Cu(II):γ-AA-FHFH complexes have been shown to have high specificity toward peroxidation,
especially the 1:2 Cu(II):γ-AA-FHFH complex.
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Table 4.7: Catalytic parameter of DTBC oxidation by 5 μM 1:1 and 1:2 Cu(II):γ-AA-FHFH with
and without the presence of 2 mM H2O2 in methanol at 25 ºC.
Cu: γ-AA-FHFH

Vmax (mM/s)

–1

–1

–1

Km (mM)

kcat (s )

kcat/Km(s mM )

0.17±0.02

0.012

0.070

0.042±0.006

0.04

0.94

0.21±0.02

0.0011

0.005

0.029±0.006

0.04

1.38

1:1 no peroxide
(Rs=0.9909)

(6.22±0.23)×10

–5

1:1 with
peroxide
(Rs=0.9928)

(2.00±0.06)×10

–4

1:2 no peroxide
(Rs=0.9980)

(5.35±0.01)×10

–6

1:2 with peroxide
(Rs=0.9735)

(2.00±0.1)×10

–4

It was hypothesized that with three γ-AA-FHFH coordinated to the Cu(II) center, due to
the saturation of Cu(II) coordination sites and steric hindrance, it is less likely for DTBC and
hydrogen peroxide to bind and perform redox efficiently. The hypothesis was confirmed by
checking the peroxidation activity of the 1:3 Cu(II):γ-AA-FHFH complex with DTBC and
hydrogen peroxide; and the results showed significant decrease in peroxidation activity compared
to the 1:1 and 1:2 complexes, with a first-order rate constant of 0.0077 s–1 and a low kcat/Km value
–1

–1

of 0.0055 s mM . Since 1:3 Cu(II):γ-AA-FHFH complex can still go through redox activity,
this indicates that the coordinated ligands may go through a certain degree of rearrangements or
detachments to allow DTBC and hydrogen peroxide binding. This can also be confirmed from
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looking at the apparent dissociation constant (Km); the Km of 1:3 complex was significant larger
than the 1:1 and 1:2 complexes, indicating a less stable γ-AA-FHFH-DTBC complex.

DTBC oxidation by 5 uM 1:1 Cu(II):AA-FHFH with 2 mM peroxide in methanol
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Figure 4.21: DTBC oxidation by 5 μM 1:1 Cu(II):γ-AA-FHFH complex and 2 mM H2O2 in
methanol at 25 ºC.

189

DTBC oxidation by 5 uM 1:2 Cu(II):AA-FHFH in methanol with 2 mM peroxide
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Figure 4.22: DTBC oxidation by 5 μM 1:2 Cu(II):γ-AA-FHFH complex and 2 mM H2O2 in
methanol at 25 ºC.

DTBC oxidation by 5 uM 1:3 Cu(II):AA-FHFH with 2 mM peroxide in methanol
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Figure 4.23: DTBC oxidation by 5 μM 1:3 Cu(II):γ-AA-FHFH complex and 2 mM H2O2 in
methanol at 25 ºC.
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Table 4.8: Catalytic parameters of DTBC oxidation by different ratios of Cu(II):γ-AA-FHFH
complex with the presence of H2O2.
kcat/Km

Cu(II):
γ-AA-FHFH

Vmax(mM/s)

Km (mM)

kcat (s–1)

(s–1 mM–1)

0.042±0.006

0.04

0.94

0.029±0.006

0.04

1.38

1.4±0.3

0.0077

0.0055

1:1 with peroxide
(Rs=0.9928)

(2.00±0.06)×10

–4

1:2 with peroxide
(Rs=0.9735)

(2.00±0.1)×10

–4

1:3 with peroxide
(Rs=0.9879)

(3.8±0.2)×10

–5

Since both DTBC and hydrogen peroxide can bind to Cu(II):γ-AA-FHFH complex
through the Cu(II) center independently and exhibit pre-equilibrium enzyme like kinetics, the
system can now be considered as a bi-substrate system. Hanes analysis was performed to further
understand the dynamic between the two substrates, revealing how the binding of one substrate
influences the other substrate. In Figure 4.24, various concentrations of hydrogen peroxide were
mixed with increasing concentrations of DTBC and 5 μM of 1:1 Cu(II):γ-AA-FHFH complex in
methanol, and their corresponding rates were monitored. The resulted rates were plotted against
DTBC concentration (Figure 4.24). The data was further processed by plotting [DTBC] against
and fit to Equation 10 for Hanes analysis (Figure 4.25):
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Equation 4.10
(

)
(

)(

)

In the equation, v0 is the experimental velocity and Vmax is the maximum velocity.
and

are the apparent dissociation constants for H2O2 and DTBC, respectively of the

ternary (H2O2)(DTBC)-Cu-L.

is the intrinsic dissociation constants for H2O2. These

constants were collected from secondary plots of slopes vs. 1/H2O2 and y-intercepts vs. 1/H2O2
(Figure 4.26).
DTBC oxidation by 5 uM 1:1 Cu(II)-AA-FHFH in methanol with varying peroxide concentration
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Figure 4.11: Hanes analysis of DTBC oxidation by 5 μM of 1:1 with Cu(II):γ-AA-FHFH
complex in the presence of H2O2 in methanol at 25 ºC.
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Hanes analysis replot: DTBC oxidation by 5 uM 1:1 Cu(II)-AA-FHFH in methanol with varying peroxide concentration
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Figure 4.25: Linear plot of Hanes analysis of DTBC oxidation by 5 μM of 1:1 with Cu(II):γ-AAFHFH complex in the presence of H2O2 in methanol at 25 ºC.
Hanes analysis replot: slope vs 1/[H2O2]
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Figure 4.12: Re-processed plots of the y-intercept (left graph) and slope (right graph) values from
Figure 4.25 with respect to [H2O2].
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From the secondary plots of slope vs. 1/H2O2 and y-intercept vs. 1/H2O2,

.

.

were calculated based on Equation 4.11 and 4.12 and their dissociation constants are 1.62,
0.004 and 23.46 mM respectively (Table 4.7).
Equation 4.11
𝑝

(

)

Equation 4.12
𝑖 𝑡 𝑐 𝑝𝑡

(

)

In a bi-substrate system, the ratio between the apparent and intrinsic dissociation constants
for each substrate can provide useful information of how the binding of one substrate influences
the binding of another substrate. The ratio between the apparent and intrinsic dissociation
constants

for DTBC is 42.5, while for H2O2 is 14. The result indicated that the binding of

both substrates to Cu(II):γ-AA-FHFH complex were enhanced by the presence of the other,
especially for DTBC (

= 42.5), the large difference between the intrinsic and apparent

dissociation constants suggested that DTBC binding to Cu(II):γ-AA-FHFH complex was
enhanced greatly by the presence of hydrogen peroxide, while DTBC binding to complex was not
influenced by the presence of DTBC that much. (

of H2O2 = 14). The significant decrease

(from 0.17 mM to 0.004 mM) in the apparent dissociation constants of DTBC was observed in the
appearance of hydrogen peroxide, confirming that hydrogen peroxide can greatly promote the
binding of DTBC to metal complex. The apparent and intrinsic dissociation constants for DTBC
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and H2O2 as well as their ratio of

determined by Hanes analysis suggest that Cu(II):γ-AA-

FHFH can act as a distinctive artificial peroxidase model.
Table 4.9: Hanes analysis results of Kapp and Kint of H2O2 and DTBC.
Kapp (mM)

Kint (mM)

Kint/Kapp

HO

1.62

23.46

14

DTBC

0.004

0.17

42.5

2

2

Concluding Remarks
In this chapter, the structure and activity relationship of two different Cu(II) containing
synthetic chemical systems were investigated. In the first project, a macrocyclic compound of
multidentate cyclophosphazene with six imidazole containing arms was complexed with Cu(II)
and exhibited pre-equilibrium enzyme-like kinetics toward both oxidation and peroxidation of
catechol, mimicking catechol oxidase. The kinetics results showed high specificity toward
catechol among various catechol derivative substrates.
In the second project, the metal binding and catalytic activity of a new peptidomimetic
design of γ-AA-FHFH were studied. Cu(II) can form 1:1, 1:2 and 1:3 stable complexes with γAA-FHFH and perform oxidation chemistry with and without the presence of hydrogen peroxide.
The result showed high specificity toward peroxidation than oxidation, allowing it to be used as a
ratification peroxidase model.
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